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SHORT SUMMARY 
 
Caffeine in cosmetic products such as shampoo and lotion can stimulate hair growth. 
Recently, it was shown that nanoparticulate formulations have better penetration into 
hair follicles. Moreover such particulate formulations to stimulate hair growth are not 
available commercially. Therefore in this study, two systems have been developed. 
The first was a particulate formulation loading caffeine by utilizing biocompatible and 
biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and chitosan. 
The second was a model of hair shafts containing nanoparticles (NPs) to prove that 
such model hair follicles can be visualized by photoacoustic microscopy. Results 
revealed that there is an interaction between chitosan and caffeine suitable for drug 
loading. Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning 
Calorimetry (DSC) and solubilization showed that this interaction is based on 
complex formation. NPs characterization showed that NPs have a spheric shape. 
NPs from chitosan-PLGA showed good properties in terms of particle size and 
distribution. Loading of caffeine was increased by using chitosan up to 19% EE. 
Caffeine release from NPs is slower than from the pure complex allowing a longer 
time frame for continious drug release. For imaging of NPs in model hair follicle 
(voids in agarose gel), PLGA NPs loading magnetite were prepared. These NPs 
could be successfully imaged by photoacoustic microscopy inside the model hair 
follicle.  
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KURZZUSAMMENFASSUNG 
 
Koffeinhaltige Haarwaschmittel, können bekanntermaßen das Haarwachstum 
stimulieren. Das Koffein wirkt dabei im Haarfolikel. Seit kurzem ist bekannt, dass 
partikuläre Formulierungen topisch appliziert besser in Haarfollikel penetrieren als 
Lösugen. Derzeit ist jedoch keine koffeinhaltige, partikuläre Darreichungsform 
verfügbar. In der vorliegenden Studie wurden zwei unterschiedliche Systeme 
entwickelt. Das Erste war eine partikuläre Formulierung mit Koffein. Hierzu wurden 
biologisch abbaubare und kompatible Polymere wie PLGA und Chitosan verwendet. 
Das zweite System sollte es ermöglichen die Partikel im Haarfollikel mittels 
photoakustischer Mikroskopie zu visualisieren. Dafür wurde ein Modell-Haarschaft 
entwickelt, sowie Partikeln, die einen guten Kontrast ermöglichen, hergestellt. Die 
Interaktion zwischen Chitosan und Koffein wurde mittels Infrarot-Spektroskopie, 
Kalorimetrie, sowie mittels Löslichkeitstest untersucht. Die Wechselwirkungen 
zwischen Chitosan und Koffein beruhen auf Komplexbildungen und erlauben eine 
Beladung der Partikel (19%EE). Die Partikel weisen eine geeignete Größe, 
sphärische Formen und schmale Größenverteilungen auf. Freisetzungsversuche 
zeigten eine verzögerte Freisetzung von Koffein aus NP im Vergleich zu reinen 
Komplexen. Zur Visualisierung der Partikel in Modellhaarfollikeln (Hohlräume in 
Agarosegel), wurden diese mit Magnetit-PLGA NP beladen. Die Partikel konnten 
mittels photoakustischer Mikroskopie in den Modelfollikeln visualisiert werden. 
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I. INTRODUCTION 
 
1.1 Hair loss problem in human life 
Hair loss can happen to men and women. Patients are usually afraid of 
experiencing it, because hair loss can lead to baldness [1]. The influencing factors 
causing hair loss are shortly reviewed in terms of the conditions of the hair in the 
follicles and the biosynthesis of hair which impact to the fragility of hair. Testosterone 
and dihydrotestosterone are androgenic hormones which are involved on hair loss. 
Overall, hair loss is influenced by internal factors which ranging from enzymes to 
hormones and external factors [2-5]. 
 
1.1.1 Internal and external factors causing hair loss 
Internal factors involve genetic reasons controlling the metabolism of 
hormones and active substances relevant for hair growth. The gene Fgf5 is 
responsible to encode the transcription factor for expression of fibroblast growth 
factor 5 (FGF5). This growth factor plays an important role in the proliferation of hair 
follicles. Three types common of baldness are due to genetic reasons: The first is 
androgenic alopecia which can be seen anytime after puberty [6,7]. Usually the 
problem will increase by increasing age. The second is telogen affluvium which is 
often associated with genetics and hair loss occurs especially due to many hair 
follicles suddenly stopping growing because of hormone imbalance (e.g., pregnancy) 
[6,8,9]. Both these types of baldness happen in sequence until all hair is lost. The 
third type is alopecia areata as shown in Fig.1 which indicates the spot or patchy 
baldness [10,11]. 
Other internal factors were thyroid imbalance, allergic reactions and diabetes 
mellitus. When thyroid imbalance occurred, high or low thyroid concentration can 
interrupt the biosynthesis of testosterone and dihydrotestosterone that influences the 
hair growth. Hair loss happened when testosterone is converted to 
dihydrotestosterone [12]. Allergic reaction as the manifestation of hypersensitivity 
reaction impacts on the activation of progressive fibrosis of the perifollicular sheet 
occurs in lesions [13,14]. Diabetes mellitus can also cause hair loss. The growth of 
hair is influenced by the concentration of glucose which can interact with keratin of 
hair follicle which is known as glycosylation. Diabetes also influence the blood 
I. Introduction 
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circulation to hair follicles affecting the ability of the hair follicle to form metabolites 
[15-18]. This also reduces the likelyhand of hair growth due to malnutrition [15-17]. 
 
Figure 1. Patchy hair loss “common type of alopecia” (image included with permission of volunteer)   
 
External factors are the factors out of the human body such as substances 
and environmental conditions which impact on the human body. External factors 
involve psychic disorder, consumption of drugs such as chemotherapeutics and such 
simple issues as hair styling. Psychic disorder because of stressful daily life can also 
lead to several diseases including hair loss. Many works in modern life style lead to 
less spare time for cooling down the metabolic reaction of the body. To support these 
activities, the body also needs good nutrition for respective metabolic action. Lack of 
protein and vitamin intake can cause hair loss. Therefore consuming sufficient 
nutrition is necessary. Especially vitamins of vegetables and fruits play a role in 
supporting the strength of hair root [19]. Consumption of anti cancer drugs such as 
derivatives of cisplastin, aclarubicine and doxorubicine reduce the proliferation of hair 
cells by being toxic especially to proliferating cells [20-22]. Hair styling is another 
factor which impacts on the growth of hair especially when chemicals and mechanical 
equipment are involved [23]. 
 
1.1.2 Prevention and treatment of hair loss 
 The natural way to prevent hair loss is to make it become healthy. Low hair 
vitalization and dandruff formation can increase the probability of hair loss. All efforts 
in order to maintain vitalization and to diminish dandruff formation are traditional way 
that people applied since long time ago [24,25]. 
 The treatment of hair loss is typically connected with an effort to reduce the 
concentration of dihydrotestosterone [26]. On stem cells, there are receptors which 
can bind testosterone. Afterwards, stem cells in the presence of testosterone [27] 
induce the production of specific ligands interacting with natural killer cells (NK cells). 
The ligands are proteins of stem cells also activating monocytes which are then 
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involved in hypersensitivity and cause inflammation as trigger for the degradation of 
the root of hair follicle. As consequence, hair follicles can not grow [28]. The condition 
when the hair follicle can not grow is known as miniaturization of the hair follicle. At 
the basal layer of hair follicles the dermal papillae is located. It contains fibroblasts 
which can regulate hair growth. The fibroblasts have androgen receptors. The larger 
sensory nerve branches and the blood vessels that nourish the skin are also located 
in the dermal papilae. This layer is an important part to inhibit the change of 
testosterone to dihydrotestosteron by using active substances such as caffeine 
[29,30] . Based on this information, the strategy to treat the hair loss is by inhibiting 
the conversion of testosterone to dihydrotestosterone. For this purpose, caffeine and 
also estradiol have been used [26,31]. Treatment of hair loss has also already been 
conducted by using commercial products such as lotions, creams, hair sprays and 
shampoos [32].  
 
1.1.3 Caffeine as stimulating agent to stimulate hair growth 
 Rubiaceae plants are used in pharmaceutical application since long time ago 
as well as in beverages. These plants have several bioactive compounds such as 
caffeine which belongs to the alkaloid purine. As an alkaloid, Caffeine is obtained in 
varying quantities in beans, leaves and fruits of plants such as coffee, tea, cacao, 
and cola [33]. The presence of caffeine in those plants is to defend against 
pathogens. People use the leaves of tea (Fig.2) for common consumption as well as 
coffee, cola and cocoa bean. These plants are also used in commercial products. 
These products are legally unregulated in nearly all jurisdictions even though 
containing psychoactive substances [34,35].  
 
 
Figure 2. Camellia sinensis is well known as tea plant. Image was taken in private garden in Bandung, 
Indonesia.       
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Caffeine consumption improves the physical endurance towards reduced drowsiness 
and restoring alertness, cognitive function, particularly vigilance, mood and 
perception of fatigue [25,33] . 
 
 Caffeine is a white powder with a hexagonal crystal structure of alkaloid 
purine. Caffeine has a molecular weight of (Mw) = 194.19 Da and the monohydrate 
has the Mw = 212.12 Da. The melting point of caffeine is 238°C. As can be concluded 
from Mw which was schetched in Fig.3 the chemical name is 1H-purine-2,6-dione, 
3,7-dihydro-1,3,7-trimethylpurine (C8H10N4O2) with C 49.48%, H 5.19%, N 28.85%, O 
16.48%[36] .  
  
 
 
 
 
Figure 3. Molecular structure of caffeine 
 
 As a central nervous system (CNS) stimulant, caffeine can increase brain 
activity by blocking the receptor for neurotransmitters such as dopamine, serotonin, 
acetylcholine, glutamate and γ-aminobutyric acid. Regarding hair growth, caffeine 
does not act directly to the main pathway of hair synthesis. However, caffeine and 
cAMP have a similar structure. Under physiologic condition, the concentration of 
cAMP is decreased by dephosphorylation reaction. In the presence of caffeine, 
dephosphorylation can be inhibited and therefore the concentration of cAMP is 
increased [31,37].  
 
1.2 Topical and follicular nanoscale drug delivery systems 
 The barrier function of human skin imposes physicochemical limitations to the 
permeation of drugs that can cross this barrier. For a drug to be delivered passively 
via the skin is difficult. An adequate lipophilicity is necessary to enhance the 
permeation [38,39]. However, a strategy has been developed to direct delivery based 
on particulate formulations to hair follicles [40]. This application has an advantage for 
an implementation of topical and follicular drug delivery systems. The investigations 
I. Introduction 
 
- 10 - 
have been conducted to evaluate this new, innovative, and convenient dosage form 
to target hair follicles [41]. 
 
1.2.1 Topical nanoscale drug delivery systems 
 Topical drug delivery systems are systems used to mainly apply drugs on the 
skin to obtain localized effects at the site of application. Topical drug administration is 
supported by the ease of administration and need to take into consideration the skin 
structure as described in the following. Skin as the largest organ, has an area of 1.7 
m2 and approximately 4 kg in weight or about 5.5% of the body mass [41,42].  
 
Figure 4. A schematic sectional view of skin which involves stratum corneum (SC), viable epidermis 
and dermis (Image is adapted from [43]) 
 
Skin is known as the outer barrier between the body and the environment and 
protects the body from external chemicals and pathogens. Skin is made up of three 
cellular layers as is shown in Fig.4. Each of them has its own structure and function. 
The outermost cellular layer of the skin is the epidermis which is composed of the 
viable epidermis consisting of living cells and the non-viable stratum corneum (SC): 
cornified cells forming a densely packed layer being the strongest barrier of the skin. 
The dermis lies directly underneath the epidermis and consists of compact 
connective tissue nerved with blood and lymph vessels. This formation supplies the 
epidermis with nutrients and removes absorbed exogenous substances acting as 
sink. The subcutaneous fatty tissue in dermis as well as other skin layers, consist of 
loose connective tissues, and its dimensions vary greatly. Topical drug administration 
 
Stratum Corneum 
 
 
 
 
 
Viable epidermis 
 
 
 
 
 
 
 
 
 
 
 
Dermis 
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gained attention as the skin offers an easy and hence convenient route having great 
potentials to deliver drugs compared to other drug administration such oral, rectal 
and parenteral [44]. 
 Interestingly, for topical application, nanoparticles (NPs) are already used in 
cosmetics [45]. Talking about terminology of nanoparticle, nano means small 
originating from the Greek term for dwarf. Materials which have dimensions between 
1 and 100 nm can possibly show unique properties enabling novel applications. 
Nanotechnology is the creation or use of the nanometer-sized materials [46,47]. In 
this thesis the usage of nano’ will be extended with respect to nanomedicines where 
also sub-micron ranges are considered to be part of it.  
Although NPs in cosmetics are commercially available, it is still under debate if 
penetration into the skin is happening and to which extend. Nevertheless, several 
results of investigation about penetration NPs across the skin were reviewed [48-50]. 
Several studies investigated the penetration of inorganic NPs such as gold NPs [51], 
lipid-based NPs [52] such as liposomes [53], transferosomes [54], ethiosomes [55], 
solid lipid nanoparticles (SLNs) [56], nanostructured lipid carriers and surfactant 
based systems such as nanosomes [57], micelles [58], and nanoemulsion [59].  
Based on the investigations regarding the penetration of NPs into the skin, 6 
nm AuNPs showed much higher extent than 15 nm AuNPs. Furthermore, it indicated 
a minimal effect of the vehicle on particle penetration [51,60,61]. The investigation of 
topical application of Fluorescein-PLGA NPs with size 320 nm reported that particles 
were only distributed on the surface of the skin. The measurement was conducted by 
CLSM and revealed that particles located near to the lipid layer around the 
corneocytes [62]. In conclusion, only very small particles seem to be able to 
successfully penetrate into the deeper skin layers. The determination of the amount 
of NPs in the SC could be done by tape-stripping [62,63]. Furthermore, the 
experimental set up for a penetration experiment for NPs were also studied. For 
instance, exposure times of at least more than 6 hours were recommended for future 
studies on skin penetration of NPs. These obtained informations are very important 
for the basic understanding of the interaction of NPs with the skin barrier [51,64]. This 
would be of use for future pharmaceutical and clinical applications, e.g. designing 
optimal topical and transdermal delivery systems. Additionally, some drugs have 
been evaluated to be delivered into the skin; for instance the evaluation of anti aging, 
vaccine and anti malignant melanoma [65-67].  
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1.2.2 Penetration pathways across the skin 
Substances delivered into the skin involve three major pathways as shown in 
Fig.5. The possible routes are transcellular, intercellular and transfollicular pathway. 
The transcellular pathway is considered to be of minor importance for dermal 
absorption due to low permeability of certain substances through the corneocytes 
[68]. In this transport pathway, substances have to partition from hydrophilic 
corneocytes to the lipid layers of the SC repeatedly resulting in a very slow process 
[69]. The intercellular pathway is considered as the predominant pathway for most 
substances. In this case, substances diffuse within the continuous intercellular lipid 
domains of SC [70,71]. In contrast to the corneocyte structure which is compact, the 
lipid domain pathway can absorb the substances faster than corneocytes and also a 
higher amount of the substances can be absorbed. Furthermore, this pathway can be 
an alternative especially in the presence of penetration enhancers [51]. It is known 
that the permeability of corneocytes increases due to alteration of keratin structure. 
However, nowadays the transcellular pathway has been investigated and may be 
more relevant to evaluate new formulations for dermal therapy [72]. 
 
                    Figure 5. Scheme of penetration pathways (Image is adapted from [73]) 
  
 
As obvious from Fig.5 the third pathway is the skin appendages offering a 
direct passage into deeper skin layers. A high density of blood vessels around the 
hair root and the absence of the SC make this an intriguing pathway especially for 
Blood vessels 
Dermis 
Epidermis 
  Stratum Corneum 
Drug 
Transcellular Intercellular Transfollicular 
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the hair follicles also showing the possibility to be permeated by drugs [74-77]. Some 
research was focused on the evaluation transfollicular drug delivery [78]. More 
detailed explanations about transfollicular pathway will be given in the next chapter 
1.2.3.   
 
1.2.3 Transfollicular pathway for drug delivery systems 
 Transfollicular pathway can deliver drug substances and particles into hair 
follicles. A respective image of a hair follicle is shown in Fig.6. Hair follicles are 
embedded in the epidermis extending deep into the dermis which provides a much 
greater actual area for potential absorption below the skin surface. 
 
Figure 6. Light microscopy image of hair follicle (image was depicted with help of Christiane Mathes at 
Biopharmaceutics and Pharmaceutical Technology, Saarland University).  
 
The structure of the hair follicles is described as a complex structure which is formed 
by three common parts: dermal papilae, bulge and sebaceous, and also the 
infundibulum [79]. Each part represents the distinct program of differentiation for 
follicle morphogenesis during the embryonic cycle. The dermal papilae in basal layer 
is the most important layer. This layer is covered by the follicular ephithelium. The 
dermal papillae contains specialized cells, so-called fibroblasts, that regulate hair 
growth. Above this layer, are located the bulge area and the sebaceous glands [80] . 
The next part is the infundibulum. From recent evidence about regulation of hair 
growth is known that the infundibulum area also has a function to regulate follicular 
growth and differentiation [81]. The location of bulge, sebaceous gland and 
infundibulum are schematically shown in Fig.7.  
Cosmetic products have been applied on the surface of skin but 
pharmaceutical dosage forms are facing the problem to deliver drug into the skin. To 
bring the drug across the stratum corneum is not an easy task. However, hair follicles 
Hair Follicle 
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give a significant contribution to the penetration which is known as transfollicular 
pathway [82,83]. In the past decade there was not much attention to this pathway 
[84]. A study about non particulate formulation was done to investigate its ability to 
penetrate hair follicles. The substance chosen for this study was estradiol. It is a 
poorly soluble, neutral compound with log octanol-water partition coefficient of logP = 
2.29 and a water solubility of 0.0003%. In 2002 the sandwich model with SC 
membranes for a Franz diffusion cell experiment was described. By using this SC 
sandwich, putting two sheets of SC on top of each other, there is only a negligible 
chance for a direct connection of two openings (hair follicles) across both membranes 
because of the random distribution of hair follicles on the skin surface. The result 
showed that the permeation through the sandwich was much reduced rather than 
that of a single skin membrane (SC) [85]. 
 
 
             Figure 7. Scheme of sebaceous gland, bulge, hair matrix and infundibulum of hair follicle  
             (Image is adapted from [86]) 
   
The group of Jürgen Lademann at the Centre for Experimental and Applied 
Cutaneous Physiology, Charite University of Medicine Berlin, Germany, investigated 
the delivery of cucurmine as substance for topical application. The presence of 
cucurmine was determined by using confocal laser scanning microscopy (CLSM) of 
skin biopsies. It could be shown that the substance could penetrate by using follicular 
pathway [83].  
Bulge 
Sebaceous gland 
Infundibulum 
Dermal papillae 
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 Furthermore, the transfolicular pathway was found to be accessible for sub-
micron particles. Hence these systems can be used as drug delivery systems to 
specifically target the hair follicles. This specificity might turn the nano- and sub-
micron carriers into important drug delivery system for the skin. A study about the 
penetration of TiO2 microparticles contained in sunscreens was conducted to 
determine their ability to penetrate hair follicles by using tape-stripping as well as by 
using X-ray fluorescence microscopy. It could be shown that these particles 
penetrated into the hair follicles [87] . Further investigations have even demonstrated 
that NPs have a better penetration than non-particulate formulations[80] . Regarding 
the particles size, microparticles of size 3–6 µm showed a tendency to aggregate in 
the hair follicles [88,89] . Particles in the size of 750 nm showed a homogenous 
distribution in the hair follicles [88]. Lademann reported in 2009 that particles sized 
300–600 nm penetrate efficiently into hair follicles than larger particles [90]. This size 
range corresponds to the approximate size of the hair cuticula which is 530 nm for 
human hair and 320 nm for pig hair (which is assumed to play an essential role in the 
permeability process by a pumping process due to the movement of the hair) [90].  
Also particles of ~100 nm in size were found to be able to penetrate into the 
hair follicles after sunscreen application [86]. Even smaller particles with sizes as 
small as 40 nm were found to penetrated deeper into the follicle and could also reach 
the follicular epithelium [91]. These small particles allow also to penetrate in the 
sourrounding tissue. According to the definition of NPs as particles being around 1–
100 nm it can be concluded that NPs are better than microparticles to address 
cellular internalizsation around the hair root for instance in langerhans cells for 
possible vaccination [92]. 
 The underlying mechanism for the superior particle penetration was explained 
to be due to the hair working as a geared pump in the hair follicle area. Hence the 
movement of the hair drives the particles deep along the hair into the hair follicle. On 
the other hand, the investigations conducted by Lademan in 2006 and Otberg in 
2007 revealed that hair follicles also represent an efficient storage for long term 
which keep those particles in reservoir [62,80]. 
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1.3 Particulate formulation as drug delivery systems 
 Nanotechnology has found applications in nearly all fields leading to significant 
technological advantages that can be applied such as in the pharmaceutical field for 
preparing and characterizing nanoparticulate formulations. Particulate formulations 
are stabile products and they have large potential to target and control the release of 
encapsulated drugs for instance due to different ways of interaction. Many efforts are 
focused on the development of these particulate formulations [93]. 
 
1.3.1    Current status of polymeric nanoparticles 
 Polymeric nanoparticles (NPs) are NPs which were prepared by using 
polymers. For pharmaceutical application, biodegradable and biocompatible 
polymers are preferred. The advantages to use such polymers are because of that 
the degradation of these polymers to biologically acceptable molecules that are 
metabolized and removed from the body using normal metabolic pathways. These 
biodegradable polymers also are well known as safe and bio-tolerant because their 
products of degradation and by-products fulfill the request for little or no adverse 
reactions within the physiology of the human body. The success of loading polymeric 
NPs with drugs shows that nanotechnology can provide carrier systems which can 
and will be used for many exciting products potentially overcoming many hurdles in 
formulation technology [94]. 
 The drug is entrapped, encapsulated or attached to the NPs. Depending on 
the method of NP preparation, nanospheres or nanocapsules can be obtained [95]. 
In recent years, biodegradable polymeric NPs based on natural polymers such as 
chitosan, gelatin, alginate or synthetic polymers such as poly(lactic-co-glycolic acid) 
(PLGA), poly (anhydrides), poly (caprolactone), poly (ortho esters), and poly (amino 
acids) have attracted considerable attention as potential drug delivery systems in 
view of their applications in drug targeting especially to particular organs/tissues 
[96,97]. Among these polymers, PLGA is most often used and was already used in 
implant medical products [98]. 
 Some researchers used PLGA in laboratory scale to form NPs and it is due to 
its benign nature a promising material to be used in future pharmaceutical products. 
As can be seen from the structure, PLGA is condensed by a lactic acid block and 
glycolic acid block by ester bonds forming a block copolymer (Fig.8).  
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                     Figure 8. Molecular structure of poly(lactic-co-glycolic acid) (PLGA) 
  
The molecular weight of PLGA ranges from 5,000 to 50,000 depending on the 
composition of lactic and glycolic acid blocks. The higher the number of lactic and 
glycolic acid blocks or the respective lactide block, the bigger is the polymer. PLGA is 
a semipolar polymer which dissolves in semipolar solvents such as ethyl acetate, 
acetone, and dichloromethane. For the preparation of nanoparticles [96,99], PLGA is 
often disolved in ethyl acetate as an organic phase and the stabilizer is added into 
the aqueous phase [96].  
 For investigation of drug delivery, particles based on poly lactic acid 
derivatives such as PLGA are used. These particles could be appreciable also for the 
delivery both of hydrophilic and hydrophobic drugs. However, in the past it was 
observed that hydrophobic drug can be loaded into the polymeric NPs very well. 
However, for hydrophilic drugs, the situation is more complicated and a double 
emulsion method is preferred to incorporate hydrophilic compartments containing the 
drug in the particles [100]. Another method such as nanoprecipitation is also used for 
hydrophilic drugs [101,102]. As possible hydrophilic pharmaceutical active agents, 
therapeutic proteins and vaccines were used. Until today, there are still limited data 
concerning PLGA NPs containing hydrophilic substances [103]. Looking in the 
literature, it turns out that PLGA is often applied as a drug carrier system to study the 
delivery and targeting of colon cancer drugs. Nevertheless, its biodegradability 
makes it also a useful material for other application routes. The PLGA NP 
formulations prepared are charachterized in terms of size, dispersity index, zeta 
potential, and release profile [104]. The adjustment of these physical properties is the 
key for targeting as they correspond to the interaction with the target location of the 
NPs. The loaded hydrophilic drugs which were studied ranged from antibiotics, anti 
cancer drug, anti inflammation drugs, and therapeutic proteins including vaccines 
[48,105,106].  
 Besides PLGA, chitosan, gelatin and alginate are also relevant and important 
substances to form polymeric NPs. These polymers were grouped as natural 
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polymers. In contrast to the polymeric NPs based on synthetic polymers the natural 
polymers show a broad size distribution. Hence for basic understanding and 
investigation they are less suited and particles from synthetic materials such as 
PLGA are often preferred due to their better size distribution [107,108].  
 
1.3.2    Preparation of polymeric nanoparticles 
 The PLGA NPs are appropriate for drug delivery systems and have been 
applied because of its biodegradability ensuring that the carrier itself and its products 
do not disturb the physiologic conditions of the human body. This pharmaceutical 
important ability resulted already in a pharmaceutical product containing PLGA, 
which is being approved by national food and drug administration (FDA) [98] hence 
underlining the materials’ potential. Therefore, these NPs are used as vehicles for the 
targeted and controlled delivery of drugs. Investigations showed successfully that 
PLGA NPs are appropriate for various routes drug administration [96]. To form these 
NPs methods know from nanotechnology are used. This technology is appropriate to 
form NPs and also showed the ability to load during the process pharmaceutical 
substances in the particles. NPs based on PLGA of different physical characteristics 
such as size, distribution of particles, morphology and zeta potential can be 
synthesized by controlling the specific parameters of the synthesis. 
To load hydrophilic drugs is more difficult than hydrophobic drugs due to 
miscibility problems between the drug and the particles’ material. Nevertheless, 
Barichelo et al. in 1999 intended to evaluate the loading of hydrophilic drugs (insulin 
and valproic acid) in NPs which were formed by nanoprecipitation [102]. Another 
hydrophilic drug such as procaine hydrochloride [103] was shown to be successfully 
loaded into NPs. 
 It is known that the synthesis on NPs by available methods such as emulsion 
solvent diffusion could be used as common method for preparation of NPs based on 
PLGA. As shown in Fig.9 two phases -organic and aqueous- phase (which are 
partially miscible) are involved. Typically, the polymers are soluble in organic solvent 
and the surfactant as stabilizer is soluble in water as the aqueous phase. The organic 
phase is dropped slowly into the aqueous phase under stirring condition. A pre-
emulsion is achieved after continuous stirring for 1 h. The size reduction of the 
preemulsion the so-called nanoemulsification is conducted by transferring energy into 
the system using mechanical processes such as ultraturrax (rotor-stator principle) or  
I. Introduction 
 
- 19 - 
 
ultrasonifier from 1 minute up to 5 minutes depending on the expected size of the 
particles (Fig.9). Dilution with water allows the organic solvent to diffuse into and mix 
with water. As a result a solid particle from polymer without solvent is formed. After 
that overnight evaporation with low vapor pressure is needed to remove the organic 
solvent form the surrounding.  
The double emulsion method is a common method to address the solubility 
issues between polymer and drug and hence to encapsulate hydrophilic drugs. 
Similar to the single emulsion solvent diffusion, but in this method two emulsification 
steps are involved by using two kinds of stabilizers. Here the inner, first emulsion 
contains the drug in an aqueous environment surrounded by polymeric material 
which is then incorporated into another, larger water droplet. The dilution with water 
is also required to extract the organic solvent overnight.  
Another method to prepare polymeric NPs is nanoprecipitation which was also 
applied for hydrophilic drugs such as therapeutic proteins [102,109]. Overall the 
method is similar to the solvent diffisuoin method, but for this method miscible 
solvents are needed instead of partially soluble solvents. The polymer is dissolved in 
the organic solvent such as dimethyl sulfoxide (DMSO), ethanol or aceton. Stabilizer 
is dissolved in aqueous phase.  
The respective drug is placed in the solvent where it dissolves. When mixing 
the organic phase containing the polymer with the stabilizer-containing aqueous 
phase, the miscibility of the solvents leads to an immediate precipitation of the 
polymer. As the polymer-solvent diffuses away, the polymer collapsed and 
precipitates in the nano size because it is not soluble in water [100,102,103].      
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Figure 9. Preparation of NPs by using emulsion solvent diffusion method with ultrasonifier. Polyvinyl 
alcohol (PVA) is a stabilizer and the method can be expanded to also load magnetite particles (MT). 
 
1.3.3    Chitosan and chitosan-coated PLGA NPs 
 Chitosan-coated PLGA NPs are formed by using chitosan and PLGA. The 
coating involves positive charge of chitosan and negative charge of PLGA to mediate 
the interactions [110,111]. Chitosan is a hydrolized extract of chitin from crustaceans’ 
hardshell, such as shrimp, crabs, insects, and also mushrooms. To obtain chitosan 
the main processes which are involved are the following: first, the skin of shrimp or 
crab was washed to be deproteinated. Then the sample is washed with acid solution 
to remove the lime as demineralization process. After demineralization, the acetyl 
groups of chitin were cleaved leading to chitosan. The ratio of deacetylation 
corresponds to the positive charge coming from primary amine groups of chitosan 
[112].  
 Chitosan is poly-D-glucosamine which is composed by more than 5000 units 
of monomers (glucosamine and acethylglucosamine) with a molecular weight up to 
500 kDa (Fig.10). The monomer number from which chitosan is composed is not less 
than 16 [107]. For biomedical applications, chitosan is already used as wound 
dressing to stop bleeding and is in addition applied due to its antibacterial properties.  
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Chitosan (chit) is generally soluble in acidic solution due to the protonation of 
the amine groups. However chitosan chloride usually can also be dissolved easily in 
water of neutral pH. Therefore, for the preparation of chitosan-coated PLGA NPs, 
chitosan was added into the aqueous phase and with a simple one step emulsion 
solvent diffusion, chit-PLGA NPs can be prepared [113]. These chit-PLGA NPs have 
also been used for investigation regarding transfection of antisense oligonucleotides 
and gene delivery due to their positive surface charge [110,114]. Besides for gene 
therapy, chitosan NPs have shown a good performance to load other drug for 
example rifampicin as antituberculosis agent [115]. 
 
1.3.4 Magnetite loaded polymeric NPs 
 The importance of nanotechnology has offered many opportunities in various 
research fields. Based on imaging and therapy, particularly inorganic NPs have 
received great attention because of their outstanding properties. Metal NPs have 
many advantages over small conventional molecules that include high molar 
extinction coefficient, high resistance to photo-degradation, size/shape dependent 
and tunable absorbance/scattering properties, which can be useful for imaging and 
therapeutic approaches. Especially the size/shape dependent and tunable 
absorbance /scattering properties can enable on-demand design for imaging or 
characterization purposes of many inorganic NPs such as magnetite [116]. 
 Magnetite is iron oxide (Fe3O4) with superparamagnetic properties which 
render interesting properties as important molecule than can absorb the near infra 
red light and could be attracted with magnetic field. Paramagnetism is a form of 
magnetism where certain materials are attracted by an externally applied magnetic 
field. Paramagnetic properties are due to the presence of some unpaired electrons 
and form the realignment of the electron orientation caused by the external magnetic 
field. On the other hand, superparamagnetism is a form of magnetism which appears 
       Figure. 10. Molecular structure of chitosan with (a) deacetylated and (b) acetylated monomer   
(a) (b) 
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in small nanoparticles for instance magnetite particles. Their size is small enough that 
only one magnetic domain exists per particles. Therefore the magnetization can 
randomly flip direction at room temperature due to the thermal energy. When an 
external magnetic field is applied, their magnetic moments are aligned along the 
applied field. The interest in magnetic materials is due to their function to develop and 
serve in modern technology [99,116]. Magnetite nanoparticles (MNPs) which possess 
paramagnetic properties were already evaluated in the clinic as contrast agent [117] 
or as therapeutic option in glioblastoma [118,119] . Furthermore, the ability to direct 
and hence target these particles by local magnetic fields offers further potential 
therapeutic applications [120,121]. 
 Magnetite was also incorporated in polymer particles. In this case, the 
magnetic moment of each magnetite will be able to rotate randomly in reference to 
the orientation of the MNP. The important property for biomedical application was the 
lack of magnetization after the colloid got stable to avoid the agglomeration [122]. 
 The investigation which were conducted by Maity, 2007 and Dresco, 1999 
presented the best compromise among appropriate magnetic properties such as 
saturation magnetization, stability under oxidizing conditions and safety for biological 
application [123,124]. The US Food and Drug Administration (FDA) has already 
approved the medical product such as Feridex® and Resovist® containing magnetic 
NPs which was formed by a mixture of Fe2+ and Fe3+ [125]. 
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II. Aim of Dissertation and Experimental Design 
 
The problem of hair loss resulting in baldness is a serious health problem. So 
far there are cosmetic products as non particulate formulations such as shampoo and 
lotion containing caffeine to stimulate hair growth. In addition, cleansing creams and 
lotions containing chitosan intended to clean the skin are also available on the 
market.  
 
Even though particulate formulations were shown to penetrate better into the 
hair shafts (the target for caffeine delivery) no particulate caffeine formulation was 
described so far for such a purpose. As consequence, no cosmetic product is based 
on particles for caffeine delivery. Therefore, this research was intended to develop a 
particulate formulation using the natural polymer chitosan and the synthetic polymer 
PLGA to form chitosan-coated PLGA NPs as a carrier system loading caffeine.  
 
Hair follicles as potential target for those carrier systems require also the 
imaging of particles which penetrate into the hair follicles. Therefore, the formulation 
of nanoparticles which can be imaged in respective structures would be necessary. 
To address the problems with respect to the size of the hair follicles for imaging, a 
new approach based on photoacoustic microscopy was aimed. The follicular imaging 
with photoacoustic microscopy needs the right marker for particle visualization and 
therefore a drug carrier system containing magnetite was the next goal.  
 
Before going to the rather complex in vivo systems (animal or human skin), the 
ability to image the particles at all in hair follicles was in focus. Therefore a system 
was developed to mimic hair follicles and to image the particles in this structure ex 
vivo.  
 
Besides the overall direction of the thesis a focus on the experimental 
approach of the different chapters is described below : 
As loading of the nanoparticulate formulation was tried to be accomplished based on 
specific interactions between the drug and the carrier. This study investigates the 
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interaction between chitosan and caffeine by using FTIR and DSC measurement in 
combination with a solubilization study.  
√ It was aimed to see whether the interaction pattern involved covalent bonds or 
rather a complex formation.  
√ Once known the interaction pattern, the following work was aimed to know the 
binding capacity of chitosan which interacted with caffeine by using 
solubilization study.  
 
After identifying the basic interaction parameters preparation and 
characterization of chitosan-PLGA NPs, it was in focus to find a good formulation.  
√ The most common steps to make NPs are intended to be loading hydrophilic drug 
such as caffeine using emulsion solvent diffusion. As an organic phase has 
used PLGA which was dissolved in ethyl acetate and aqueous phase was 
chitosan and PVA solution. For control, double emulsion technique as a 
common method to encapsulate hydrophilic drug was applied.  
√ This further study also intended to characterize NPs using zeta sizer, SEM and 
AFM.  
√ The amount of caffeine in NPs was determined indirectly from the supernatant of 
suspension and directly by dissolving NPs. The release profile of caffeine from 
chitosan-PLGA NPs across a membrane was determined and compared to the 
complex alone and caffeine diffusion across a membrane.  
 
As conventional technique, such as light microscopy requires sectioning of the 
sample. Another imaging approach such as photoacoustic microscopy was in focus. 
With this approach, a material which can enhance the contrast such as magnetite is 
needed. Therefore the third part of the thesis was thought to develop a particulate 
formulation containing magnetite particles for improved contrast. This formulation 
would be applied to image the model hair follicle. As mentioned above, this model is 
necessary to establish rather than working with the complex systems of in vivo 
measurements. The workpackages for this part were:  
√ Preparation of PLGA NPs loading magnetite using two kinds of magnetite. First one 
was magnetite which stabilized with aminohexanamine and the second one was 
magnetite was stabilized with oleic acid. Single emulsion solvent disffusion 
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method was applied to the preparation of NPs. For the comparison the 
nanoprecipitation method was used.  
√ Characterization of PLGA NPs loading magnetite in terms of size, dispersity index 
of particles, zeta potential, and morphology. The presence and successful 
loading of the core of magnetite was determined by AFM and TEM.     
√ Development of the model hair shaft and imaging by using photoacoustic 
microscopy. Model of hair shaft was based on agarose. The idea was to create 
voids in the size of human hair follicles. The model hair shaft should be filled 
with suspension of PLGA NPs loading magnetite for imaging. The imaging 
measurement was conducted by using photoacoustic microscopy in cooperation 
with IBMT, St. Ingbert.  
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III. Interaction of Chitosan and Caffeine 
 
3.1 Introduction 
Several efforts were addressed to the development of cosmetic formulations 
especially when using chitosan and caffeine [126,127]. Chitosan which is 
commercially available in formulations is of high-grade quality made from shrimp 
shell by deacetylation (75-90%). Furthermore due to the positive charge, chitosan 
can interact with DNA and therapeutic proteins to avoid degradation and facilitate 
cellular uptake [128-130]. Chitosan was also used successfully to form particles 
containing theophyline derived from xanthine (alkaloid) as a lead structure [131,132]. 
However, there were no data regarding the interaction of chitosan and caffeine. 
Based on the molecular structure of chitosan and caffeine, they both have 
several polar functional groups which lead to hydrophilic properties. Usually polar 
interaction of the drugs could be categorized into dipole-dipole (Keesom) and dipole-
induced dipole interaction (Debye) which involve dipole orientation of molecules with 
polarizable dipole moments. Depending on the structure of the molecule, both types 
of interactions can take place in the underlying van-der-Waals (vdW) forces 
[133,134]. 
To study the interaction between chitosan and caffeine, the information about 
their polarity is necessary. Their polarity refers to a separation of electric charges 
leading to a molecule or its chemical groups having an electric dipole or multipole 
moment. Polar molecules interact through dipole-dipole intermolecular forces and 
hydrogen bonds and molecule polarity depents on the difference in electronegativity 
between atoms in a compound and the asymmetry of the compound’s structure. 
Furthermore, polarity of the molecules results in a number of physical properties 
including surface tension, solubility, boiling and melting points [135,136]. This polarity 
usually corresponds to hydrogen bonds forming between the hydrogen atom 
attached to an electronegative atom such as oxygen in the carbonyl functional group 
(C=O) of caffeine, and nitrogen in the amine group N-H2 of chitosan. Based on these 
theories we assumed that chitosan and caffeine can perform this kind of interaction to 
associate with eachother.  
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3. 2 Materials and Methods 
 
3.2.1. Materials  
Chitosan with 75% deacetylation and a molecular weight Mw < 150,000 Da 
was obtained from Novamatrix, Norway (Protasan UPCL 113). Centrisart with a 
molecular weight cut off (MWCO) of 20,000 Da, Vivaspin 20 which a MWCO of 
300,000 and 100,000 Da were obtained from Sartorius, Göttingen, Germany. 
Caffeine anhydrous was obtained from Sigma Aldrich, St Louis, USA. All other 
solvents and chemicals were commercially available, from the highest grade and 
used as obtained.  
3.2.2. Equipment 
UV-Vis Spectrophotometer, Lambda 35 and FTIR Spectrophotometer, 
Spectrum 400 series, PerkinElmer LAS Rodgau, Germany were used. Differential 
Scanning Calorimetry (DSC) was performed by using DSC-Q100 from TA Instrument, 
Germany. Sample holder for DSC from Hermetic Lid, Germany, Sonicator, Bandelin 
from Sonorex, Germany, Vortex Genie from Scientific Industries, Germany, 
Centrifuge, Rotina 420R from Hettich Zentrifugen, Germany, and pH meter from 
Schott, Germany was used for the different investigations.   
 
3.2.3. FTIR measurement 
To perform Fourier transform infrared spectroscopy (FTIR) measurements, 
physical mixture of chitosan and caffeine powder was used. For the comparison, the 
samples was also prepared from solution by dissolving Protasan UPCL 113 at pH 9 
to obtain 0.3% chitosan solution with 10 mg of caffeine. While stirring, the interaction 
could take place for 30 minutes at room temperature followed by lyophilization. A 
total of 3 mg of this mixture was characterized by FTIR Spectrophotometry. Pure 
chitosan and caffeine anhydrate were also used as references. 
 
3.2.4. DSC measurements 
DSC measurements were taken under nitrogen flow of 50 -100 mL.min-1 using 
a sample mass of 4 mg and heating rates of 10°C min-1. The samples were placed 
into covered aluminum holders with a central pinhole. An empty sample holder was 
used as reference and the runs were performed by heating the samples from 25 up 
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to 400°C. The samples were the physical mixture of chitosan and caffeine, chitosan 
(Protasan UPCL 113) and caffeine were used for reference.     
 
3.2.5 Determination of chitosan and caffeine by UV spectroscopy 
 Stock solution of chitosan chloride was obtained by dissolving 5 mg Protasan 
in 2 mL demineralized water. After that, into the chitosan solution, hydrochloride acid 
0.1 M was added to adjust the concentration of chitosan to 0.25 mg/mL. From this 
solution, the determination of λmax was performed by UV spectrophotometer. The 
measurement was performed in quartz cuvettes between 200 and 300 nm using an 
absorption peak of chitosan [137]. For calibration, serial concentrations of chitosan in 
hydrochloride acid 0.1 M was used to obtain the concentrations of 0, 0.006, 0.125, 
0.250, 0.350, 0.500, 0.650 and 0.750 mg/mL. For the solubilisation study, the 
permeation of chitosan through different filters was tested (Vivaspin 20 with MWCO 
300,000 and 100,000 Da and Centrisart with MWCO 20,000 Da) and the 
concentration of chitosan passed through the membrane was calculated. For the 
preparation of caffeine solution, 5 mg caffeine was dissolve in demineralized water as 
stock solution. For calibration concentrations of caffeine of 0.0015, 0.003, 0.004, 
0.006, 0.008, 0.012 and 0.024 mg/mL were used  
 
3.2.6 Solubilization study of caffeine in the presence of chitosan 
 First of all, caffeine in high amount was added to an aqueous phase at 25°C to 
determine the saturation concentration (cs) keeping the temperature constant. For 
solubilization studies, the amount of caffeine was always kept higher than cs.  
 
 
 
 
 
 
 
 
 
 
Figure 11: Scheme of the setup which was used for the determination of cs of caffeine  
              using Centrisart 20 kDa to measure the solubility of caffeine. 
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Determination of the dissolved amount of caffeine was conducted by adding different 
amounts of chitosan to the inner chamber of the Centrisart (Fig.11). A total of 60 mg 
of caffeine were suspended in 1.5 mL of demineralized water. The sample was 
transferred to the outer tube of the Centrisart. Then 0.5 mL of chitosan with several 
concentrations 0.075, 0.150 and 0.300 mg/mL were added separately to the inner 
tube with membrane MWCO 20,000 Da as shown in Fig.11 and followed by 
centrifugation with 1000 x g for 90 minutes. Hereafter, the amount of caffeine in the 
supernatant was determined by UV spectrophotometer. 
 
3.3. Results and Discussion 
 
3.3.1. Physical interaction between chitosan and caffeine  
 Protasan UPCL 113 used in this experiment, is commercially available, has an 
average degree of deacetylation of more than 75% and its molecular weight 
distribution ranges from 10,000 to 400,000 Da. This type of chitosan chloride is 
soluble in water also in pH range 5 to 9. At pH 11 Protasan precipitates. In the pH 
range where Protasan is soluble its amine (-NH2) functional group can possibly 
perform an interaction with the carbonyl group (C=O) present in caffeine. 
  The determination of an interaction between chitosan and caffeine is the first 
indication which is a necessary for the loading of caffeine into chitosan-PLGA NPs. 
Therefore, the interaction between chitosan and caffeine was addressed looking at 
IR spectra and the glass transition temperature.  
 First of all, the samples were prepared and the interaction patterns were 
analyzed by using a procedure to determine caffeine [138]. As shown in Fig.12, the 
FTIR spectra display the typical peaks from the functional groups. The stretching 
bond of carbonyl is typically found in the range between 1447-1705 cm-1 [139]. For 
caffeine, the stretching bond of carbonyl was found at 1646 cm-1 right in the range as 
expected. The stretching bond of methylamine is typically found in the range between 
992-1260 cm-1 [140]. For chitosan, stretching bond of methylamine was found at 
1020 cm-1 also right in the range as expected. Both wavenumbers did not change 
their position for the mixture. The complex formation is supported by the change of 
intensity of the peaks in the spectrum allowing to conclude that the interaction 
involves hydrogen bonds between the amine groups of chitosan and the carbonyl 
groups of caffeine. Furthermore, it can be concluded, that the interaction does not 
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involved formation of covalent bonds as there was no shift in the wavenumber (cm1) 
observed (Fig.12). Possible covalent bonds would occur between amine and carboxyl 
groups (HO-C=O) in the presence of high temperature. As caffeine only has a 
carbonyl group and the interaction took place at room temperature (~23°C) the 
formation of a covalent bond was not likely. The wavenumber above 2750 cm-1 
represents the stretching of –OH and C-C of chitosan. Blue lines are the complex of 
chitosan and caffeine and the stretching –OH and C-C were revealed as shown in 
Fig.12.  
 
 
 
In Fig.13 the DSC measurements are displayed. It can be seen that water evaporates 
at the peak below 100°C in the chitosan spectrum (grey line). Typically this water is 
associated with hydrophilic groups in the amorphous chitosan. Caffeine as anhydrous 
base did not show that peak (black line) as expected. Endothermic phase transition 
from solid to liquid took place below 250°C for chitosan and caffeine. The 
disappearance of the endothermic peak of caffeine at 310°C indicated that caffeine 
dissolved in the molten chitosan which is an indication that chitosan and caffeine 
form a complex.  
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Figure 12 : FTIR spectra of chitosan, caffeine and chitosan-caffeine as physical mixture and prepared 
from solution. The respective wavenumbers 1020 and 1646 cm-1 are highlighted by thed dashed line 
indicating the strechting of the amine group and the carbonyl group, respectively.  
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Figure 13. DSC measurements of pure chitosan, caffeine and both together to identify a possible 
physical interaction between caffeine and chitosan  
 
3.3.2 Solubilization study of caffeine by using chitosan 
          This step was performed to support the information that was already obtained 
regarding the physical interaction that was explained above. At first, the change of 
dispersion turbidity containing saturated caffeine was performed. Fig.14 shows that 
(Fig.14A), the saturated solution containing insoluble caffeine results in a turbid 
solution. Afterward, chitosan was added to this solution of caffeine resulting in clear 
solution (Fig.14B).  
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Figure 14. Saturated caffeine become clear solution because of solubilization by adding chitosan. 
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This reduction in turbidity is caused by additional dissolved, suspended caffeine by 
the presence of chitosan. Since the free caffeine interacts with chitosan, forming 
complexes, the non-dissolved, solid caffeine can dissolve to reach the saturation 
concentration.  
Besides this first indication regarding turbidity, the capability of chitosan to 
solubilize caffeine was investigated. To test the solubilization capability of chitosan 
for caffeine, a filter setup was used. In this setup caffeine and chitosan were in two 
different compartments separated by a membrane. For the compartments Vivaspin 
system or Centrisart system was tested. Vivaspin has one tube and in that tube 
located the membrane with certain MWCO (300,000 and 100,000 Da). Protasan 
UPCL 113 has molecular weight <150,000 Da. The amount of chitosan passed 
through the membrane can influence the amount of caffeine which was solubilized in 
this experiment. Therefore, before going to the solubilization study, the determination 
of chitosan passing the membrane is necessary. Chitosan was measured using the 
absorption maximum at 207 nm in acidic solution of pH 1 (0.1 M HCl) [137]. At high 
wavelength close to 300 nm there was no absorption as shown in Fig.15. Therefore, 
the peak at 207 nm works well for the determination and quantification of chitosan as 
can be seen from the Fig.15.  
 
 
 
 
 
Figure 15. Absorption maximum of chitosan between 200 and 300 nm and the respective calibration 
curve of chitosan based on this absorption. 
 
Based on result in Fig.16, Vivaspin is not suitable for solubilization study 
because chitosan can pass through the membrane. On the other hand, Centrisart 
presents small MWCO to hold chitosan (Fig.16). With centrisart (20,000 Da) system, 
chitosan has not passed through the membrane.  
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Figure 16. Amount of chitosan that could pass through the filter of Vivaspin and Centrisart with 
different MWCO.  
 
Centrisart (20,000 Da) was investigated furthermore to perform solubilization study 
(hence allowed to determine the caffeine concentration with interference from the 
polymer). Subsequently, determination of chitosan and caffeine can be determined 
by using UV spectrophotometry. 
In Fig.17 we can see the peak of caffeine which also could be determined by 
using UV spectrophotometry. Caffeine has the maximum absorption at 272 nm in 
demineralized water. Based on the two spectra of chitosan and caffeine, it was 
concluded that chitosan did not interfere with the caffeine determination because 
chitosan does not absorb at 272 nm (Fig.15). 
 
Figure 17. Local absorption maximum of caffeine at λ= 272 nm and the calibration curve of caffeine 
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concentration of caffeine as shown in Fig.17. The linear curve was achieved with R2 
= 0.9989. Based on this calibration curve, the amount of caffeine which was 
solubilized by chitosan could be calculated.  
First of all the saturation concentration was determined as reference point for 
caffeine solubility at 25°C. In Fig.18 cs is shown as dashed line at a concentration of 
26.2 mg/mL which is in agreement with literature data [141]. The concentrations of 
chitosan in contact with the saturated caffeine solution were then varied from 0.075 
mg/mL to 0.30 mg/mL. Subsequently, using several concentration of chitosan ranging 
from low (0.075 mg/mL) to high (0.3 mg/mL), the solubility of caffeine was influenced 
by the concentration of chitosan. This trend was shown in Fig.18 that indicating 
roughly a linear concentration between chitosan concentration and additional 
dissolved caffeine amount (R2 = 0.9413). Hence, chitosan clearly has the capability 
to solubilize caffeine. 
 
 
 
 
 
 
3.4 Conclusions 
Fourier transform infrared spectroscopy (FTIR), differential scanning 
calorimetry (DSC) measurements and a solubilization study could demonstrate an 
interaction between caffeine and chitosan. The elucidation of the interaction 
betweencaffeine and chitosan which was already investigated by FTIR measurement 
indicated that it was a complex formation and there was no peak shift of the carbonyl 
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Fig. 18: Solubilization of saturated caffeine by adding chitosan. 
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group at 1646 cm-1 and the methyl amine group of chitosan at 1020 cm-1. The 
formation of such a complex was supported by DSC measurements where the glass 
transition temperature revealed that molten caffeine is soluble in molten chitosan at 
temperatures above 200°C. Furthermore, the changes observed in turbidity of the 
saturated solution of caffeine becoming clear when adding chitosan was another 
clear hint for this interaction taking place between caffeine and chitosan. UV 
measurements further allowed quantifying the effect of chitosan on the solubility of 
caffeine. Initially, without chitosan, the solubility of caffeine was 26.2 mg/mL in water 
at room temperature. By adding chitosan up to 0.3 mg/mL the concentration of 
caffeine solubilized was found to be 30.07 mg/mL. So, this amount of chitosan (0.3 
mg/mL) could interact with caffeine and increase the saturation concentration by ~4 
mg/mL.  
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IV. Nanoparticulate Formulation Intended for Hair Follicle Targeting 
 
4. 1. Introduction  
 Investigation of the use of drug carrier systems to treat hair loss is still in early 
stage. In Human life, hair loss is a condition which occurs more frequent along with 
time and increasing activities of human leading to stress conditions during daily work. 
When a person experiences stress without realizing, so the stress condition lead to a 
weakened metabolic system. Another reason for hair loss is because of the natural 
aging process enhanced by hair care. After a hair is lost, usually the new hair can 
grow again; if not baldness will occur [142,143]. Shampoo containing caffeine, as a 
non-particulate formulation, has been available in commercial trade to stimulate hair 
growth for quite some time [31,128,144]. In general, hair follicles were believed to be 
a minor pathway for transdermal drug delivery into human skin [62,83,87,145] due to 
the small hair follicle density of an average of 0.1% [38]. Based on recent 
publications, it is known that particulate formulations show better penetration into hair 
follicles than formulations without particle [62,63]. Particulate formulations, micro and 
nanoparticles (NPs), which have been evaluated in several experiments about 
transfollicular penetration indicated that particles with an optimal size of 320 nm can 
penetrate deeply into the hair follicles [63]. However, for targeting of hair follicles, 
particles size from 500 to 600 nm are believed to be well suited [86]. Beside the 
possibility to penetrate into the hair follicles, the uptake into cells, especially 
Langerhans cells, was according to literature observed for particles of around 40 nm 
[146]. So depending on the specific need and target within the follicle different-sized 
particles could be utilized.  
 To achieve a good drug carrier system the applied materials (polymers) have a 
large impact. The utilization of natural and synthetic polymers is foremost to increase 
the capability of carrier systems for drug delivery. Until now, some natural polymers 
which have been successfully purified and synthetic polymers have been produced to 
serve the formulation of NPs [107,147,148]. There are several requirements for these 
polymers regarding regulative issues such as the biodegradability, biocompatibility 
and benign character (toxicity) as well as technological aspects such as the 
interaction between polymer and active pharmaceutical ingredient (API) influencing 
the release profile from the NPs. Based on these criteria, the polymers which were 
most extensively applied for creating nanoparticulate delivery systems over one 
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decade are poly(lactic-co-glycolic acid) (PLGA) and chitosan. NPs based on PLGA 
were usually prepared by using emulsion solvent diffusion techniques which can be 
considered the standard methodology. Nevertheless, PLGA NPs could also be 
prepared by nanoprecipitation, emulsion coalescence and spray drying depending on 
the specific goals of the formulation process [132,148-151].  
It is also known that by using PLGA, a good encapsulation has been achieved 
for hydrophobic APIs. In contrast, the encapsulation of hydrophilic drugs is not an 
easy task and influenced by several factors such as kind of the polymer, the organic 
solvents and correctly chosen stabilizers [108,115,152-154]. Nevertheless, some 
studies reported, that by optimizing these factors, hydrophilic APIs could be loaded 
into PLGA NPs by nanoprecipitation [102,103]. A combination of PLGA and chitosan 
was chosen to vary the particle properties [110,111]. For delivery purposes, the 
presence of amine functional groups of chitosan allowed to make use of the 
electrostatic effect, of hydrogen bonds, and Van der Waals forces to interact with the 
carbonyl functional group of the bioactive compound [155,156].   
In this study, preparation of chitosan-PLGA NPs was performed by using 
emulsion solvent diffusion method. Two types of homogenizer -ultrasonifier and 
ultraturrax- were evaluated as well as two types of chitosan: Protasan UPCL 113 and 
Kitozyme. In addition, PLGA NPs without chitosan were also prepared as a control. 
Based on the literature reports that the double emulsion method for preparation of 
NPs could load hydrophilic drugs, this method was also used for comparison. Pure 
chitosan NPs without PLGA were prepared by using the crosslinker tripolyphosphate 
(TPP). NPs were then characterized regarding size, polydispersity index, zeta 
potential and morphology. The appropriate formula in terms of size distribution and 
morphology was selected to be loaded with caffeine. Subsequently, NPs were 
purified and % encapsulation efficiency as indirect EE of caffeine from the 
supernatant was calculated. In terms of particles, the direct EE and loading of 
caffeine was determined after NPs were dissolved. And finally, the release profile of 
caffeine from the NPs was monitored.  
 
 
 
 
 
IV. Nanoparticulate Formulation Intended for Hair Follicle Targeting 
  
 
- 38 - 
4. 2. Materials and Methods 
 
4.2.1. Materials 
 PLGA 50:50 (Resomer RG 503) with a molecular weight Mw of 24,000 - 38,000 
Da was obtained from Evonik Industries (Darmstadt, Germany). Chitosan chloride 
with a degree of 75% deacetylation (Protasan UPCL 113) with a molecular weight < 
150,000 Da was obtained from Novamatrix (Norway), chitosan base (Kiomedine®) 
with a degree of 75% deacetylation was obtained from Kitozyme (Herstal, Belgium). 
Polyvinyl alcohol (PVA) (Mowiol 4-28) was obtained from Kuraray specialties 
(Frankfurt, Germany), Pluronic F68 was obtained from BASF (Ludwigshafen, 
Germany), Tripolyphosphate (TPP) was bought from Merck, Darmstadt, Germany, 
cellulose membranes with a MWCO 12,000 – 14,000 Da were bought from Medicell 
International LTD (London, UK) and caffeine anhydrous came from Sigma Aldrich (St 
Louis, USA). For scanning force microscopy muskovite mica was obtained from 
Plano Planet GmbH, Wetzlar, Germany. Silica wafers were obtained from Wacker 
Chemie, Germany. NSC 16/50 non-contact silicon cantilevers, MikroMasch, 
Cambridge, UK. All other solvents and chemicals were commercially available and of 
highest grade.  
 
4.2.2 Equipment 
Zetasizer Nano ZS from Malvern Instruments, Worcestershire, UK was used to 
determine the size and the zeta potential of the particles. The morphology of NPs 
was determined by Atomic Force Microscopy (AFM) using a Nanoscope IV Controller 
from Digital Instruments, Bruker Corporation, Billerica, USA and scanning electron 
microscopy (SEM) using a EVO HD from Carl Zeiss, Jena, Germany. 
  
4.2.3. Preparation of nanoparticles 
The common method to form NPs loading hydrophilic drug is based on a 
double emulsion[100] . It was formed by using 2.5 mL PVA 2.5 mg/mL containing 
6.25 mg/mL caffeine which was dropped into 40 mg/mL PLGA in 2.5 mL ethyl 
acetate. The mixture was then placed in an ice bath under stirring for 1 hour at 750 
RPM. To produce a nanoemulsion, ultraturrax at 13,200 RPM was applied for 10 
minutes. The second emulsification step was formed by using Pluronic F68 as 
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stabilizer with concentrations of 15 and 20 mg/mL (2.5 mL for each). The resulting 
emulsion was stirred over night at 500 RPM to evaporate the organic solvent. 
Emulsion solvent diffusion method was used to prepare the chitosan-PLGA 
NPs as described before [110,111]. In brief, the emulsion was prepared by using 
PLGA 40 mg/mL in 2.5 mL ethyl acetate as organic phase. The aqueous phase 
consisted of 2.5 mL of 25 mg/mL PVA solution, chitosan 0.3 mg/mL, and 6.25 mg/mL 
caffeine. The aqueous phase was dropped into ethyl acetate as organic phase. The 
mixture was placed in an ice bath under stirring for 1 hour at 750 RPM. To produce a 
nanoemulsion, both ultrasonifier at 10% amplitude (A) with 500 Joule for 1 minute 
and ultraturrax at 13,200 RPM for 10 minutes in an ice bath were applied. The 
resulting emulsion was stirred over night at 500 RPM to evaporate the organic 
solvent. For size comparison, blank PLGA NPs and chitosan-PLGA NPs were 
prepared without caffeine using the same protocol as for the single-step emulsion 
solvent diffusion. Besides Protasan, another type of chitosan - Kiomedine originating 
from mushrooms and produced by Kitozyme was also used for comparison. Pure 
chitosan NPs without PLGA core were also prepared by using ionic gelation method 
based on the crosslinker tripolyphosphate (TPP). Chitosan (Protasan) was dissolved 
in demineralized water to make a stock solution of chitosan (0.625 mg/mL) and TPP 
was dissolved also in demineralized as stock solution of TPP (0.125 mg/mL). 
Chitosan NPs were formed by adding 2 mL TPP 0.125 mg/mL into 2 mL chitosan 
0.625 mg/mL. The resulting mixture was stirred for 4 hours.       
 
4.2.4. Purification of nanoparticles and %EE of caffeine  
5 mL suspension of NPs was placed in Vivaspin-20 (Sartorius, Göttingen, 
Germany). The suspensions were purified by using a centrifuge at 14,000 x g at 
T = 8°C for 30 minutes. The supernatant were collected to determine the 
encapsulation efficiency (%EE) of caffeine by using HPLC-analysis. The mobile 
phase of HPLC was a phosphate buffer pH 2.6 and acetonitrile (90:10) with a flow 
rate of 1.2 mL/min. The HPLC column was a reverse phase column C18 with 
controlled temperature at 25°C.  
The amount of NPs was obtained from lyophilized samples. After that, this 
sample allows to quantify the loading of drug in the formulation. The loading can be 
calculated based on the amount of drug in NPs and the weight of the samples used 
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for investigation. For lyophilization, sample was pre-frozen at T = -80°C and then the 
drying process was continued by a conventional Alpha 2-4, freeze-dryer (Christ, 
Osterode, Germany). 
 
4.2.5. Size, PDI and zeta potential and morphology study of the nanoparticles 
Determination of size, PDI and zeta (ζ) potential were the common 
approaches to determine the properties of the NPs. After evaporation of the organic 
solvent, the NP suspensions were characterized regarding size, ζ-potential, and 
polydispersity index (PDI) using dynamic light scattering (DLS) from Malvern 
Instruments, Worcestershire, UK. NPs were purified by Vivaspin20 and the filtered 
NPs were washed with 0.2% trehalose which also acted for the pellet redispersant. 
The redispersed NPs were analyzed regarding their morphology. The morphology of 
NPs was visualized by AFM and SEM measurements. Before the measurements, 
NPs were dilluted in demineralized water using vortex and dried overnight at room 
temperature. AFM measurements were done with a Bioscope with a Nanoscope IV 
controller (Veeco Instruments, Bruker, Germany). Samples were prepared by 
dropping 20 µL of diluted sample on freshly cleaved mica. The NPs were investigated 
after drying under ambient condition with tapping mode using a tip with cantilever of k 
= 40 N/m and a resonance frequency of ~250 kHz. For SEM measurements, the 
samples were dried under ambient conditions and coated with gold using a Quorum 
Q 150 ES sputter coater at 40 mA for 50 s in order to render the sample conductive, 
improving the image quality (thickness of the gold coating was less than 20 nm). For 
visualization a ZEISS EVO HD 15 was used in high vacuum mode, applying an 
acceleration voltage of 5 kV.  
 
4.2.6. Dissolving nanoparticles and determination of loading  
Several organic solvents such as ethyl acetate, dichloromethane, 
dimethylformamide (DMF), tetrahydrofurane (THF) and dimethylsulfoxide (DMSO) 
were tested to dissolve chitosan-PLGA NP. As a control, PLGA NPs were used in 
this experiment. PLGA dissolves in DMSO and ethyl acetate and chitosan is only 
soluble in acidic solution. DMSO is soluble in water but ethyl acetate is only partially 
soluble in water. The NPs were placed into 0.1% acetic acid, followed by DMSO to 
obtain a one-phase system. This approach required heat treatment at T = 60°C for 9 
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hours and 15 minutes sonication successively. Afterwards, the amount of caffeine 
loaded was determined (direct method).  
 
4.2.7. In vitro release study 
For the release study, Franz Diffusion Cells were set up. For the study the 
same volume of acceptor and donor compartment was used. The drug can diffuse  
effectively into the acceptor compartment and the speed of stirrer bar also the sink 
condition of each cell were important factors for release study using Franz Diffusion 
Cell. Performing release study followed the procedure described before [157] . The 
donor compartment was filled with 40 mg lyophilized NPs containing caffeine 
suspended in 0.5 mL demineralized water. A Medicell membrane with MWCO 14,000 
Da was placed in between donor and acceptor compartment. The acceptor 
compartment was filled with 12.5 mL of phosphate buffered saline (PBS) pH 7.4. The 
caffeine released to the acceptor compartment at room temperature was sampled 
using a long syringe; a Pasteur pipette was used to refill the acceptor compartment 
through the sampling port. The amount of released caffeine was determined by 
HPLC analysis. In this determination, mobile phase phosphate buffer pH 2.6; 
acetonitrile = 90:10 was used, the retention time was 5.1 min, at λmax was 262 nm. 
The shift of λmax from 272 to 262 nm due to the influence of acetonitrile and 
phosphate buffer in mobile phase of HPLC.  Flow rate was 1.2 mL/min and injection 
volume 20 µL. For comparison, the passive diffusion of pure caffeine and from a 
mixture of caffeine-chitosan was also determined.  
 
4.3 Results and Discussion 
 
4.3.1 Size, PDI, and zeta potential of the prepared NPs 
 After we established the binding capacity of chitosan to caffeine, we 
developed a formulation with NPs loading caffeine using biodegradable and 
biocompatible polymers (chitosan and PLGA) by using the established solvent 
diffusion evaporation method (single emulsion). 
 The common type of drug to load PLGA NPs is hydrophobic. Nevertheless, 
hydrophilic drugs can also be loaded into PLGA NPs using double emulsion[102, 
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103] . Therefore double emulsion was also used to encapsulate caffeine as reference 
method. 
 Both methods -single and double emulsion- have used PLGA as polymer due 
to its well-known properties. Resomer RG 503 is a PLGA which has 50% glycolic and 
50% of lactic acid groups and a molecular weight Mw of 24,000 to 38,000 Da. Based 
on literature, PLGA in combination with chitosan is able to form PLGA NPs (core) 
coated with chitosan. This system has been described to be a good drug carrier 
system [110, 111, 115, 158]. In addition, chitosan-PLGA NPs prepared using the 
standard method (single emulsion) were described showing better PDI than other 
approaches. Besides the formulation of hybrid particles based on PLGA and 
chitosan, chitosan NP could also be formed by combining it with alginate, gelatine 
and crosslinker molecules. Furthermore, pure chitosan particles were prepared using 
the crosslinker tripolyphosphate (TPP) which was chosen due to its good safety 
profile. 
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Figure 19. Size and charge of PLGA, chitosan-PLGA, and TPP-chitosan particles. The dashed 
line represents a guide to the eye to show the reference size from pure PLGA NP. 
 
First of all, double emulsion as common method to load polymeric particles 
with hydrophilic drugs was used to prepare PLGA NPs loading caffeine. This 
preparation method was then compared to a single emulsion preparation containing 
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forming chitosan-PLGA NPs using the specific interaction between chitosan and 
caffeine for loading. As shown In Fig.19 size and ζ-potential of NPs prepared by the 
double emulsion methods with two concentrations of the stabilizer Pluronic F68 are 
depicted. The two double emulsion formulations resulted in particles smaller than 
300 nm and with a PDI of 0.16 indicating a relatively broad size distribution of the 
carriers. However, single emulsion method for chitosan-coated PLGA NPs showed 
smaller sizes (d ~ 250 nm) and a very good PDI of ~0.06. As control, blank PLGA NP 
were prepared yielding the smallest and most well distributed particles with sizes of 
208 nm and a PDI of 0.02. Particles prepared by the ionic gelation method (chit-
TPP), using tripolyphosphate (TPP) showed sizes of more than 300 nm and the worst 
size distribution (PDI = 0.21) (Fig.19). Looking a bit closer at the size distribution 
(Fig.20) the chit-TPP NPs had the largest range with a full width at half maximum 
(FWHM) of 205.49 nm. The second largest FWHM was found for PLGA NPs 
prepared by double emulsion with particles showing a FWHM of 166.38 nm, followed 
by chit-PLGA NPs with FWHM = 155.25 nm and the control PLGA NPs with the 
smallest distribution (FWHM = 123.75 nm).  
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         Figure 20. Size and distribution of chit-PLGA, PLGA, chit-TPP and PLGA double emulsion  
 
The zeta potential of the different preparations followed the expected trends 
displaying negative ζ-potentials for the preparations without chitosan and positive ζ-
potentials for the chitosan containing formulation because of the amine groups of 
chitosan (Fig.19).  
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Based on the results of the characterization of NPs size, PDI and ζ-potential, 
especially chitosan-TPP NPs did not show good properties with a too broad 
distribution (PDI = 0.21). Therefore, these particles were not further investigated. The 
preparation of PLGA NP and the chitosan NP was further evaluated with respect to 
the dispersion method and the type of chitosan used. 
 
   Table 1. Ultraturrax and Ultrasonifier as Homogenizer  
Ultraturrax Ultrasonifier Samples 
Size (nm) PDI ζ−Pot (mV) Size (nm) PDI ζ−Pot (mV) 
PLGA NP 
 
208.2 ± 1.91 0.042 ± 0.002 -10.31± 0.045 202.6 ± 1.104 0.036 ±  0.001 -10.01 ± 0.038 
Chit-PLGA NP 
 
267.8 ± 4.49 0.081 ± 0.014 17.72 ± 0.048 253.1 ± 2.621 0.066 ± 0.012 17.94 ± 0.042 
   Standard deviation of (n=3) 
 The effect of homogenizing method on the properties of NPs is shown in 
Tab.1. There was no difference with respect to size and PDI found. However, using 
the ultraturrax the 10 minutes preparation time caused an increase in temperature to 
20°C with ice bath and even to 42°C without ice bath. On the other hand, ultrasonifier 
used for 1 minute only showed an increase in temperature to 11°C with ice bath 
(without ice bath was 18°C) resulting also in NPs with very good particulate 
characteristics. Since this method was less time consuming while providing a 
reduced temperature effect and both methods gave comparable size distributions the 
method based on the ultrasonifier was chosen for further experiments.  
 
                             Table 2. Impact of the kind of chitosan (Protasan and Kitozyme) on the NP properties  
Characterization Samples 
Size (nm) PDI ζ−Pot (mV) 
Protasan 255.5 ± 2.718 0.068 ± 0.015 17.40 ± 0.062 
Kitozyme 276.5 ± 4.301 0.092 ± 0.060 14.32 ± 0.091 
                    Standard deviation of (n=3) 
As there is more than one kind of chitosan - Protasan and Kitozyme- the 
impact of the two types of chitosan was studied. Protasan was able to produce NPs 
with better PDI than those prepared with Kitozyme (Tab.2). Overall the differences 
were small. However, one important disadvantage of Kitozyme is its solubility profile 
restricting the preparation. The preparation of Kitozyme solution was more time 
consuming because to dissolve this chitosan in acidic pH needs sonication for 2 
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minutes followed by stirring for 15 minutes. In contrast, Protasan dissolved 
immediately in demineralized water. To keep the temperature change of the process 
low, an ice bath was needed. In addition, the solubility of caffeine is also reduced by 
reducing temperature.  
 
Hence lower preparation temperatures seemed to be meaningful for 
preparation as caffeine solubility changes. Taken all these data into consideration, 
chitosan-PLGA NPs which were formed by single emulsion method using Protasan 
and an ultrasonifier to form the nanoemulsion were chosen for drug loading. All 
further investigations as determination of the encapsulation efficiency, the loading 
capacity and the release of caffeine were performed with this formulation.     
 
4.3.2. Purification of nanoparticles, %EE of caffeine and morphology study 
Supernatant after purification of chitosan-PLGA NPs loading caffeine was 
collected. The amount of caffeine in the supernatant was quantified by using HPLC-
analysis. EE was calculated based on the following formula : 
 
 
 
 
 
EE of caffeine from chitosan-PLGA NPs was found to be (19 ± 1.1)%. In 
comparison the EE of caffeine in PLGA NPs prepared by the double emulsion 
method was only (14 ± 1.1)%. Obviously, the addition of chitosan forming chitosan 
NPs using single emulsion led to an increased EE compared to the double emulsion 
approach.  
Based on the AFM and SEM images it could be demonstrated that the 
morphology of chitosan-PLGA and PLGA NPs was spherical with a smooth surface 
(Fig. 21). From Fig.21, analysis of the average size of NPs was conducted by using 
Section Analysis of the Nanoscope software. Average size of NPs from AFM image 
(Fig.21a) of chit-PLGA NPs was 215.31 nm and the PLGA NPs (Fig.21b) were 147.8 
nm.  
The fact that the chit-PLGA NPs were larger in size was expected due to 
previous results [110] and the increased viscosity of the aqueous phase due to the 
EE   =   total amount of caff  - amount of caff in supernatant    x 100% 
                                   total amount of caff 
caff is caffeine 
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presence of chitosan. Analysis of the average sizes of NPs using SEM images, chit-
PLGA NPs (Fig.21c) yielded an average of 164.7 nm and the blank PLGA NPs 
(Fig.21d) were found to be 135.5 nm by using ImageJ. All the NPs from SEM images 
were smaller than the hydrodynamic sizes determined by light scattering because of 
the drying and vacuum process. This also explains the differences between SEM 
measurements, performed in vacuum, and AFM measurements done under ambient 
conditions. In addition, for AFM measurements the unknown effect of the tip 
geometry is always present increasing slightly the object size. Nevertheless, the 
particle sizes are all in the same size range within the variations due to the 
techniques and support the obtained narrow size distribution. 
 
Chitosan-PLGA NPs PLGA NPs 
A 
 
B 
 
C 
 
 
D 
 
                Figure 21. AFM images of chit-PLGA NPs (A), PLGA NPs (B) and SEM images of chit     
                   PLGA (C) and PLGA NPs (D).  
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4.3.3. Dissolving of chitosan-PLGA nanoparticles to determine the loading  
 To determine the amount of drug incorporated in the particles it is necessary 
to dissolve the particles, evenly disperse the drug and then separate the drug from 
the other components for analysis. Therefore, the dissolution step of the particles is 
essential to evaluate directly the amount of loaded drug. 
After purification and lyophilization of chitosan-PLGA NPs the samples were 
obtained as powders. To suspend them, demineralized water was added followed by 
vortexing. By this step, we obtained the NPs well suspended as a stable suspension. 
These suspensions were used for the dissolving step. However, dissolving the NPs is 
not always an easy task. For instance, in literature is already described that even 
plain PLGA NPs do not always completely dissolve by using good organic solvents 
such as DMSO [159]. Having this in mind, it was not surprising that the hybrid PLGA 
NPs with chitosan and stabilizers [160] were more difficult to dissolve. Chitosan, 
representing the outer layer of the particles [111], is well soluble in acidic solution.  
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                     Figure 22.  Turbidity measurement of chit-PLGA NP suspension (grey line) and the 
                         absorption signal (≙ light scattering) after dissolving chit-PLGA NPs (black line). 
                                                      
 
Therefore an approach based on an immersion in an acidic solution was used 
first. An acetic acid solution 0.1% at T = 60°C for 9 hours was applied, followed by 15 
minutes sonication. Afterwards, DMSO was added to the system to obtain an one-
phase system of drug and polymeric entities (particles were completely dissolved).  
The successful dissolution of the NPs was investigated by turbidity measurement 
using UV/Vis spectroscopy. Before dissolution, the particles dispersed in water 
clearly showed a scattering signal (upper curve in Fig.22). After acetic acid-DMSO 
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treatment, the signal strongly drops indicating completely dissolved chitosan-PLGA 
NPs because of reduced or no colloidal scatteres. Light scattering data of the 
dissolving NP showed clear solution (no measured absorption signal in the range 
from 360-800 nm). This result showed that the problem regarding dissolving 
chitosan-PLGA NPs could be solved using such a two-step dissolution process. After 
knowing the condition to dissolve chitosan-PLGA NPs, we could continue to 
determine the amount of successfully loaded caffeine into the NPs. The solution of 
dissolved NPs was centrifuged at 14,000 x g for 90 minutes to remove large objects 
and filtered with Chromafil filter 0.2 µm to avoid agglomerated material eventually 
present. Afterward, 100 µL of this solution was diluted with 900 µL mobile phase 
(buffer phosphate pH 2.6; acetonitrile = 90:10). Detection wavelength was 262 nm 
with retention time of 5.1 min and flow rate was 1.2 mL/min with injection volume of 
20 µL. The amount of caffeine was determined and the %EE by this direct method 
was found to be (12.33 ± 1.7094)% based on the following formula : 
 
 
 
The loading of caffeine was 0.059, indicating that in 100 mg NPs 5.9 mg caffeine 
were contained. The loading was calculated based on the following formula 
 
 
 
Based on this result, the %EE and the loading is low as typical of hydrophilic drug. 
However this values show that chit-PLGA NPs can load caffeine. Due to more 
specific localization of NPs in hair follicles, the small amount of NPs is sufficient.  
 
4.3.4. In vitro release study 
 Franz Diffusion Cells were prepared to perform release studies according to a 
method which was described previously [161]. For this approach, lyophilized NPs 
loading caffeine were suspended in demineralized water and the caffeine released to 
the acceptor compartment at room temperature was monitored [157]. The sampling 
 Loading     =    amount of caffeine in NPs         
                                         total weight of NPs 
%EEdirect   =          amount of caffeine in NPs              x 100% 
                          amount of caffeine added in the beginning 
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was performed by a long syringe and Pasteur pipettes were used to refill the acceptor 
compartment through the sampling port. The membrane with MWCO 14,000 Da was 
placed in between acceptor and donor compartment. The concentration and hence 
the amount of released caffeine was determined by using HPLC analysis. 
The influence of chitosan-PLGA NP loaded caffeine led to a prolonged and 
slower release of caffeine from the particles as shown in Fig.23. Up to 24 hours, 40% 
caffeine was rapidly released (burst release) and the remaining amount of caffeine 
was continuously released until at 56 h a plateau was reached. The missing amount 
of caffeine should be still associated with chitosan. Based on literature the 
encapsulation of drug into NPs can influence the pattern of drug release [162]. 
Obviously, chitosan coating PLGA NPs could reduce the burst release of caffeine 
from the particles. This is because of the interactions between caffeine and chitosan 
as shown in chapter 3. Furthermore, according to recent reports chitosan was found 
after freeze drying changing its swelling behavior. Chitosan was observed to show a 
time dependent hydration and swelling. As consequence the release of caffeine 
incorporated in such a swollen chitosan layer would be prolonged compared to the 
non-entrapped caffeine. Pure caffeine, as expected, showed the fastest passive 
diffusion across the membrane up to 6 h and achieved 75% released amount. For 
the mixture of caffeine-chitosan, passive diffusion of caffeine was slower in the first 6 
hours than the diffusion across the membrane for pure caffeine but faster than the 
caffeine diffusion from the chit-PLGA NPs. After 24 hours the maximum of permeated 
caffeine was achieved at ~ 70 %. This was the same level as found for free caffeine 
and represents the equilibrium level. The slower permeation across the membrane 
from the chit-PLGA NP might be due to the particulate nature. In addition to the 
interaction between chitosan and caffeine the geometric restrictions of the chitosan 
layer at the particle interface together witht the swelling will contribute and further 
slow down the release from the particles. This permeation profile across the 
membrane indicated that caffeine was interacting with chitosan and that the resulting 
complex (caffeine-chitosan or caffeine-chit-PLGA NP) slowed down release and 
hence the free diffusion of the drug. 
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Figure 23. Release/diffusion profiles of caffeine across a membrane for chit-PLGA NP loading 
caffeine, pure caffeine and the physical mixture of caffeine and chitosan.  
 
 
4.4 Conclusions 
 In this study, we propose a new biodegradable nanocarrier for loading the 
hydrophilic drug caffeine. The NPs which were prepared showed spherical shape 
with sizes of 208±1.104 nm for pure PLGA, 254±2.621 nm for chitosan-PLGA, and 
351±12.051 nm for TPP-chitosan. The polydispersity index of the two NP 
preparations based on PLGA was better than that of the ionic gelated chitosan. 
Therefore, this preparation method was not further investigated. The zeta potential of 
the NP based on PLGA was found to be negative whereas the chitosan-containing 
NPs were, as expected, positive. To load the hydrophilic drug the double emulsion 
approach and the single emulsion set-up were used and compared. The 
encapsulation efficiency of caffeine to the chitosan-PLGA NPs was determined to be 
(19 ± 1.1)%. It was higher than that found for the double emulsion method without 
chitosan (only ~14%). Thus the interaction between caffeine and chitosan enabled a 
higher loading. Therefore, this system seems to be better suited for an applicaton 
targeting hair follicles. The loading of caffeine into chitosan-PLGA NP could also 
prolong the release of caffeine compare to the passive diffusion of caffeine and 
mixture of caffeine-chitosan. This reduced release of the drug could further support a 
reservoir effect of the particles when accumulating in hair follicles. 
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V. Photoacoustic Microscopy to Image Model Hair Follicle 
5.1 Introduction 
To bring drugs across the skin is one of the biggest challenges for a drug 
delivery system [163-165]. The optimization of such systems is difficult, because skin 
is well known as a good barrier regarding to the dense, poorly permeable 
corneocytes and overlapping alignment of the cornified cell layers of skin. Another 
difficulty is that not all drugs could overcome the epidermis by penetration. It is 
dependent on the partition and diffusion coefficient of the active pharmaceutical 
ingredient (API). APIs with high partition coefficient can pass through the stratum 
corneum (SC) and for APIs with low partition coefficient it is difficult to penetrate SC. 
Molecular weight (MW) of the API plays also an important role for skin penetration. 
500 Dalton (Da) is the molar mass often stated as exclusion limit for dermal 
penetration and permeation through the SC [38]. Against these difficulties, the 
alternative strategy is to collect the API in the hair follicle as an intriguing approach 
gaining more attention for targeting API because the hair follicles are known as an 
efficient storage and penetration pathway for topically applied substances [145]. 
Follicular penetration for targeting with NPs is a relatively new topic of research. 
Using this pathway, the NP loaded with API can enter the hair follicles and then 
release the API without need to disturb the skin barrier (non-invasive delivery) 
[87,92,145]. 
Visualization of sectioned skin could be performed by using confocal laser 
scanning microscopy (CLSM). However imaging entire hair shafts in skin using 
CLSM faces drawbacks due to the size and the tilted orientation of the hair shaft in 
the skin [166]. Nevertheless, an imaging of intact hair follicles would be necessary 
and helpful to identifying the presence and location of the NPs. Usually sectioned 
skin was used for CLSM but finding intact hair follicles is a time consuming task by 
this technique. On the other hand, photoacoustic microscopy allows visualizing such 
large scale structure non-invasively [167-169]. A necessity for sufficient quality of 
images of photoacoustic microscopy is the usage of a contrast agent such as 
magnetite (iron oxide) [170]. Iron oxide can absorb the near infra red light and emit 
ultrasound. This ultrasound waves can then be detected and converted to an image 
by using an ultrasound-transducer [171,172]. Recently, researchers have focused to 
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load iron oxide into NP made from biodegradable polymer such as dextran, gelatin 
and PLGA to obtain paramagnetic properties of the NPs. These properties are 
especially advantageous with respect to cleaning and collecting of NPs 
[169,173,174]. The polymer of choice in this study is the synthetic polymer poly 
(lactic-co-glycolic acid) (PLGA) which is a well-known biodegradable and 
biocompatible pharma polymer [96,175,176]. This property is a basic requirement for 
therapeutic usage of NPs [44,99,106]. Thus magnetite is intended to be incorporated 
into PLGA NPs drug carrier. 
Another advantage for the application of NP as drug delivery system is the 
reduction of undesired side effects of the API [177-179]. A controlled size distribution 
is a central requirement for a pharmaceutical product [180-182]. Stronger restrictions 
are laid upon the selection of the methods that will be used for NP production, 
avoiding harmful substances during the production process. Additionally, the stability 
of NP should be considered for the delivery system [183,184].  
 For the preparation of NPs, the emulsion solvent diffusion and 
nanoprecipitation are known as common methods [100,102,184]. Emulsion solvent 
diffusion and nanoprecipitation methods were used to prepare NPs. The effect of 
magnetite concentration on the formulation was investigated, in terms of the physical 
properties of NPs. Hydrodynamic size, dispersity index and zeta potential were 
determined by dynamic light scattering (DLS). The morphology of NPs was 
determined by scanning electron microscopy (SEM) and atomic force microscopy 
(AFM). The localization of magnetite in the PLGA NPs was determined by AFM and 
transmission electron microscopy (TEM). Furthermore, the magnetite-PLGA NPs 
were applied for imaging of the model hair shaft by using photoacoustic microscopy. 
5.2. Materials and Methods 
5.2.1. Materials 
 PLGA Resomer RG 503 (50:50) was obtained from Evonik Industries. Its 
molecular weight is 24,000 - 38,000 Da. Polyvinyl alcohol (PVA) Mowiol was obtained 
from Kuraray, Pluronic F68 was obtained from BASF, agarose and oleic acid-
stabilized magnetite in toluene were purchased from Sigma Aldrich, 
aminohexanamine-stabilized magnetite in dimethyl formamide (DMF) was obtained 
from the Department of Physical Chemistry, Saarland University. For scanning force 
microscopy, as sample support muskovite mica was obtained from Plano Planet 
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GmbH, Wetzlar, Germany. Silica wafer was obtained from Wacker Chemie, 
Germany. NSC 16/50 non-contact silicon cantilevers from MikroMasch, Cambridge. 
Syringes (Sterican-26G) with diameter of 0.45 mm were obtained from Braun Medical 
AG, Emmenbrücke, Germany. All other solvents and chemicals were from the 
highest grade and commercially available. 
5.2.2. Equipment 
Zetasizer Nano ZS from Malvern Instruments, Worcestershire, UK. Atomic 
Force Microscope (AFM) with a Nanoscope IV (Digital Instruments), Bruker 
Corporation, Billerica, USA. Scanning electron microscopy (SEM) using a SEM EVO 
HD 15 from Carl Zeiss and sputter Quorum Q 150 RES from Judges scientific, UK. 
Transmission Electron Microscopy (TEM) JEM-2010, JEOL GmbH, Eching, 
Germany. Confocal laser scanning microscope ZEISS LSM 510 META, Carl Zeiss, 
Jena, Germany. Optoacoustic signals of pulsed Nd-YAG laser system (H7000) was 
provided an optical microscope (Olympus IX 81), Tokyo, Japan. 
5.2.3 Preparation of PLGA NPs loaded with aminohexanamine-stabilized magnetite   
To prepare nanoparticles containing magnetite, nanoprecipitation method 
[185] was used. 25 mg/mL PLGA and 1 mg/mL of magnetite particles were dispersed 
in acetone under stirring for 30 minutes. Nanoprecipitated particles occurred when 
this organic phase was immersed to an aqueous phase contained Pluronic F68 as 
stabilizer. The immersion process was conducted by using a syringe. Then acetone 
was evaporated overnight at room temperature (~22°C).  
To compare with nanoprecipitation another method for the preparation of NPs 
-the single emulsion solvent diffusion- was udsed [116,169]. In brief, 25 mg/mL PLGA 
was dissolved in ethyl acetate as organic phase. After that, 1 mg/mL 
aminohexanamine-stabilized magnetite in DMF was added to 6 mL of the organic 
phase under stirring followed by sonication for 30 minutes and vortex 2 minutes to 
achieve a homogenous suspension. To form an emulsion, the organic phase was 
dropped to the aqueous phase containing 2.5% PVA as stabilizing agent and stirred 
for 1 hour. By using an ultrasonifier with 500 J for 30 seconds, the emulsion was 
homogenized to form sizes in nm scale. Afterwards, dilution by adding 6 mL 
demineralized water allowed ethyl acetate to mix with the aqueous phase. After that, 
ethyl acetate was evaporated overnight at room temperature (~22°C). The 
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preparation was conducted by using several concentrations of magnetite: 0.5, 1, 2, 4 
and 6 mg/mL.  
To homogenize aminohexanamine-stabilizing magnetite into organic phase in 
presence of DMF, several steps were needed. Regarding this limitation, in a second 
approach, it was tried to remove and exchange DMF. Thus, aminohexanamine 
stabilizing-magnetite in DMF was diluted in isopropanol and then poured into ethyl 
acetate containing 25 mg/mL PLGA. The supernatant was separated from 
precipitated magnetite-PLGA particles. The precipitate was dispersed in 2.5 mL ethyl 
acetate. Once dispersed, the single emulsion method was conducted. Organic phase 
was added drop by drop by using peristaltic pump into the aqueous phase containing 
2.5% PVA. To emulsify this mixture, ultrasonifier with 500 J for 30 seconds was 
applied, followed by dilution with 6 mL demineralized water. Evaporation of the 
excess organic solvent was conducted at room temperature (~22°C) over night.       
5.2.4 Preparation of PLGA NP loaded with oleic acid stabilized-magnetite  
 In the previous step, the influence of removing DMF was removed. In this step, 
for comparison, the preparation of NPs was performed with oleic acid-stabilized 
magnetite in toluene which is miscible with ethyl acetate. NPs were prepared by 
using 25 mg/mL PLGA in ethyl acetate with 0.5, 1 and 2 mg/mL of oleic acid-
stabilized magnetite. The organic phase was mixed by stirring and then dropped into 
PVA 2.5% as aqueous phase by using peristaltic pump. Stirring was continued for 1 
hour. To form nano-sized NPs, homogenization by using ultrasonifier with 500 J for 
30 seconds was applied. After that, dilution was conducted by adding 6 mL 
demineralized water. Over night evaporation was applied at room temperature 
(~22°C) to remove ethyl acetate. 
5.2.5 Purification and characterization of nanoparticles 
For purification, the suspension of NPs as much as 5 ml was placed in 
Vivaspin-20 with a MWCO of 300,000 Da from Sartorius. The suspensions were 
purified by using a centrifuge at 14,000 x g, T = 8°C, for 30 minutes. Filtered NPs 
were washed and redispersed with demineralized water. For determination of the 
physical properties of resuspended NPs, they were characterized regarding size, 
polydispersity index (PDI) and zeta potential by dynamic light scattering (DLS) with a 
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). Morphologic characterization 
 V. Photoacoustic Microscopy to Image Model Hair Follicle 
 
- 55 - 
was performed by SEM an AFM. To achieve an adequate concentration of NPs for 
the microscopic measurement, suspension was diluted 1:100 in demineralized water. 
Then, for SEM measurement, 20 µL of the diluted sample was dropped on a silica 
wafer and dried under ambient conditions. The sample was then coated with a layer 
of ≤ 20 nm gold (sputter coater Quorum Q 150 ES at 40 mA for 50 s) in order to 
render the sample conductive and improve image quality. For visualization a ZEISS 
EVO HD 15 SEM was used in the high vacuum mode, applying an acceleration 
voltage of 5 kV. 
To obtain 3 dimensional information on the sample (20 µL of the diluted sample was 
dried on the freshly cleaved mica) an atomic force microscope (Bioscope SPM) with 
a Nanoscope IV controller (Digital Instruments, Bruker) was used. The NPs were 
investigated under ambient conditions in tapping mode using a tip with cantilever of k 
= 40 N/m, resonance frequency of ~250 kHz. After that, the AFM images were 
analyzed with the AFM software (Nanoscope IV version 5.12R.3).  
5.2.6 Determination of the magnetite core by using TEM, elemental analysis and 
AFM phase imaging 
 Determination of magnetite core incorporated into PLGA NPs was conducted 
by TEM, elemental analysis and AFM phase imaging. TEM sample was prepared by 
dropping the 20 µL of magnetite-PLGA NPs suspension on a copper grid. The 
sample then was dried under ambient conditions on the surface of the grid. The 
visualization was conducted by JOEL Transmission Electron Microscopy (model 
JEM-2010 instrument, JEOL GmbH, Germany). The size of the magnetite NPs was 
determined from the contrast (black spots) at the TEM image. Furthermore, 
elemental analysis allowed the identification of the materials which were incorporated 
into PLGA particles.     
5.2.7 Preparation of model hair shaft 
 The idea was to create a void structure (mimicking the hair shaft) which was 
then filled with PLGA NPs loading magnetite. Therefore a syringe was immersed into 
1.75 % agarose. After the agarose solidified, a void was obtained by withdrawal of 
the syringe. The model is composed of three layers (Fig.24). First was a based layer 
(as a foundation), second was a gel forming layer containing the void, and the third 
was a cover layer (to restrict diffusion of NPs during the CLSM and photoacoustic 
measurement). First of all, to form the based layer, 5 mL agarose was poured into 
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Petri dish. After that, to form the gel layer, 12 mL agarose was added above the 
based layer. In this layer a syringe containing the suspension of NP was immersed 
before agarose could become solid. The model hair shaft was obtained when the 
agarose became solid around the syringe. After that, the suspension of NP was 
injected slowly into the void while the syringe was removed from the agarose. 
Therefore the void was filled with the NPs suspension. The whole surface was then 
covered with a thin layer of agarose. As control, pure magnetite and blank PLGA NPs 
were used to perform photoacoustic imaging. Whereas for the CLSM imaging, the 
PLGA NPs labeled with fluoresceinamine were used. 
 
               Figure 24. Sketch of the reparation of model hair shaft containing magnetite-PLGA NPs  
 
5.2.8 Imaging model hair shaft by using CLSM and Photoacoustic Mcroscopy 
 For CLSM measurement using a confocal laser scanning microscope ZEISS 
LSM 510 META, Carl Zeiss, Jena, Germany, agarose gel samples were sliced in 
cubic blocks and placed on the cover slip. The slice was placed in the microscope 
with the model hair shaft being parallel to the objective. This preparation was 
necessary to omit the limitations regarding the focal distance of the objective. The 
excitation was performed by using λ = 488 nm. The fluorescence signal was 
collected after a band-pass 522/35.                                                                                                                                                                                                        
Optoacoustic imaging is a selectively new method that relies on a good 
absorbtion of light (in near infrared region). The sample is irradiated by short laser 
pulses in the sub-nanosecond range generating broadband acoustic signals as a 
result of the thermoelastic effect. These signals propagate through the sample and 
can be acquired with adequate ultrasound transducers. When compared with 
Zoom 
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conventional ultrasound imaging, optoacoustic techniques have the advantage of 
higher contrast since optoacoustic signal amplitudes are proportional to the local 
absorption coefficient µa. Since the absorption is dependent on the concentration of 
absorbing NPs, this effect can be used in order to assess the suitability of different 
particle types (magnetite, magnetite-loaded polymer) as contrast agents. 
For assessing the detectability of the different NPs types, an optoacoustic 
microscope has been used. Photoacoustic microscopy setup was developed by 
Fraunhofer Institute for Biomedical Technology (IBMT), ST Ingbert, Germany. 
Optoacoustic signals were generated by a pulsed Neodymium-doped Yttrium 
Aluminum Garnet (Nd-YAG) laser system (H7000). The data were amplified using a 
single channel hardware platform (AMI-US/OA, Kibero GmbH) to obtain the 
images[186] . For imaging of the prepared samples (model hair shaft loaded with 
different NPs), two different optoacoustic imaging systems were used. The device 
developed by Fraunhofer IBMT is based on an inverted optical microscope (Olympus 
IX 81, Tokyo, Japan). It can be used as conventional optic microscope, acoustic 
microscope or optoacoustic microscope. For photoacoustic microscopy, the 
measurement could directly be conducted from the Petri dish containing the gel and 
the model hair shafts.  
For acquisition of optoacoustic signals, an acoustic detection unit has been 
mounted to the microscope. It is based on a 2D piezo-scanner that allows point-wise 
acquisition of signals from the investigated sample. Signals can be acquired using 
focused high frequency ultrasound transducers. For achieving the highest resolution, 
a 400 MHz ZnO transducer with a lateral resolution of 2.5 µm developed by 
Fraunhofer IBMT is used [170]. The scanner and the transducer are attached to a 
rotating column so that a fast exchange between the optoacoustic/ultrasound 
modality and the conventional optical imaging mode is guaranteed. This is especially 
helpful when optical microscopy was used to assist the position of targeting the 
sample. 
 
5.3 Results and Discussion 
5.3.1 Preparation and characterization of size, PDI and zeta potential 
In general, the formation magnetite loaded NPs could be realized by single 
emulsion and nanoprecipitation [169,185] . Therefore, these methods have been 
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chosen to prepare the formulation of PLGA NPs loading magnetite for photoacoustic 
imaging and drug delivery [185,187].  
Applying the two different preparation methods, particles with clearly different 
properties were obtained (Tab.3). By using nanoprecipitation, the resulting NPs 
showed a broad size distribution (PDI = 0.53 ± 0.0323) even though the mean 
diameter was around 100 nm. As expected, using PLGA, the particles have negative 
zeta potential (-8.01 ± 0.81) mV [169].    
       Table 3. Hydrodynamic mean size (nm), PDI and Zeta Potential (mV) of PLGA NPs loading   
       Magnetite were prepared by nanoprecipitation and single emulsion method 
 
        Standard deviation (SD) of (n=3) 
 
On the other hand by using the same concentration of magnetite, single 
emulsion resulted in NP with good properties in terms of size and PDI. The size with 
250 nm of the particles was much larger than from the nanoprecipitation. The 
particles were mostly monodispersly distributed as can be seen (Tab.3) from the 
small PDI below 0.1 (PDI = 0.060). From this part, we chose the single emulsion 
method for further preparations. The influence of magnetite concentration was then 
evaluated for concentrations ranging from 0.5 – 6 mg/mL. Looking at the data 
(Tab.4), only the concentrations of magnetite lower than 2 mg/ml resulted in 
nanoparticles with small PDI values (monodisperse). High concentrations (4-6 
mg/mL) resulted in polydisperse NPs (PDI>0.2). Based on this result, it was 
concluded that single emulsion method using magnetite up to 2 mg/mL is a well 
defined preparation which could be applied for the main work.   
         Table 4. Hydrodynamic mean size (nm), PDI and zeta potential (mV) of NPs loading magnetite  
          prepared by single emulsion method. 
  
Concentration of 
magnetite 
Mean Size  
(nm ± SD) 
Polydispersity 
Index (PDI ± SD) 
Zeta Potential  
(mV ± SD) 
 
0.5 mg/mL 212.18 ± 2.16 0.08 ± 0.02 -5.91 ± 0.35 
1 mg/mL 254.38 ± 3.88 0.06 ± 0.03 -5.44 ± 0.42 
2 mg/mL 336.29 ± 6.21 0.12 ± 0.04 -5.34 ± 0.61 
4 mg/mL 446.29 ± 8.28 0.24 ± 0.06 -4.06 ± 0.72 
6 mg/mL 1174.3 ± 12.68 0.54 ± 0.08 -3.51 ± 0.75 
           Standard deviation (SD) of (n=3)  
 
Methods Mean Size  
(nm ± SD) 
Polydispersity 
Index (PDI ± SD) 
Zeta Potential  
(mV ± SD) 
 
Nanoprecipitation 115.33 ± 5.01 0.53 ± 0.032 -8.01 ± 0.81 
Single Emulsion 254.38 ± 3.88 0.06 ± 0.027 -5.44 ± 0.42 
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Solvent extraction method which removed the dimethyl formamide (DMF) of 
magnetite stabilized with aminohexanamine, could produce particles with good size 
and PDI. In the presence of DMF, to mix magnetite with ethyl acetate needs several 
steps such vortex and sonication. Therefore for the following preparation of NPs, 
DMF was removed. For comparison, oleic acid stabilized magnetite in toluene which 
is miscible in ethyl acetate was also utilized. Single emulsion method and 
concentrations of magnetite up to 2 mg/mL were applied (based on the previous 
result).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The monodisperse magnetite-PLGA NPs were obtained by using 0.5, 1.0 and 2.0 
mg/mL (Fig.25) of two kind of magnetite (amino hexanamine-stabilized magnetite and 
oleic acid-stabilized magnetite). With a low concentration of magnetite (0.5 mg/mL) 
the mean size of particles was around 200 nm, the PDI values indicating a narrow 
distribution and the zeta potentials were slightly negative (for both kinds of magnetite 
used). Using 1 mg/mL magnetite could also result in monodisperse particles. These 
particles have mean size around 220 nm with narrow distributions (PDI 0.04) and 
they have also slightly negative zeta potentials (-5.616 mV). This method was 
obviously suitable for the preparation of PLGA NPs loading both oleic acid-stabilized 
magnetite in toluene (commercially available magnetite from Sigma Aldrich) and 
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Figure 25. Size, PDI and Zeta Potential of PLGA NP loading magnetite 
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aminohexanamine-stabilized magnetite (from Department of Physical Chemistry, 
Saarland University). The physical properties of these magnetite-PLGA NPs are 
described in Fig.25. According to Fig.25, monodisperse NPs were obtained with 
magnetite of 1 mg/mL by using single emulsion method. Therefore, these NPs were 
utilized for microscopic characterization and hair shafts imaging. 
5.3.2 Imaging NPs by SEM, AFM and TEM 
Based on the result of the zetasizer measurements, all images were taken 
from NPs which were prepared by 1 mg/mL magnetite using single emulsion method. 
SEM and AFM measurements in order to know the morphology of the NPs which 
were diluted in demineralized water.  
The SEM images (Fig.26) reveal that the NPs were spherical and the mean 
size was around 176 ± 6.92 nm calculated by freeware ImageJ (Version 1.46). The 
AFM image shown in Fig.27 allows to determine the mean size of NPs around 192 ± 
17.74 nm by section analysis. Both sizes fit to the size range of particles applicable to 
hair follicles. It was also indicating that these sizes were smaller than the 
hydrodynamic size. This might be a result of the drying process during sample 
preparation for AFM and SEM measurements.   
 
  
Figure 26. SEM images of the magnetite-PLGA NP 
 
Both SEM and AFM images showed spherical particles well distributed with respect 
to their size. As depicted in Fig.27, NP was analyzed regarding their size by marking 
the bottom and top of the pancake-like structure by using section analysis. According 
to this image s was assumed that the distance between the two arrows indicated the 
high of collapsed particle containing a magnetite core.  
 V. Photoacoustic Microscopy to Image Model Hair Follicle 
 
- 61 - 
 
 
 
Figure 27.  AFM images of the PLGA NP containing magnetite core  
 
The height was measured to be ~31 nm being a bit larger than the diameter of 
pure magnetite NP of ~20 nm (Fig.30). The differences in the value are due to the 
polymer surrounding the magnetite particles. It can also be seen that the collapsed 
particle is composed out of a thing ring (polymer) and a higher center. From this 
structure it can be concluded that the PLGA NPs contain a solid core, the magnetite 
particles. 
5.3.3 Determination of the successful loading of magnetite in PLGA NPs 
Even though we got some indication of the magnetite being incorporated in the 
PLGA particles, the key question is still to ensure if the magnetite was successfully 
entrapped. To answer the question, TEM, elemental analysis and AFM phase 
imaging were applied. TEM images in Fig.28 demonstrate that the grey spherical 
PLGA NPs (low contrast) contain black spots (high contrast) being most likely 
magnetite (Fig.28A).  
The dense particle of magnetite demonstrated a low electron transmittance 
which corresponded to the black spot. In comparison, PLGA as organic polymer has 
high transmittance therefore the NP was seen as the grey particle. Three analyzed 
particles containing magnetite in Fig.28A have the size of approx. 155, 225 and 125 
nm which were analyzed by ImageJ.  
core 
Vertical distance 31 nm 
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Figure 28. TEM images of the PLGA NPs with magnetite (A), elemental analysis 
                  of PLGA NPs loading magnetite (B) and the elemental signature of the TEM grid (C) 
 
To identify the iron oxide, elemental analysis was conducted on one particle 
loading magnetite. The NP is a single particle and quite far from another NP therefore 
free space could be used as control and the information based on this data that iron 
peaks has come from PLGA NP loading magnetite. The strong iron signal from PLGA 
NP loading magnetite came from magnetite core (Fig.28B) and the TEM grids did not 
have the spectra of iron. The copper and chrome signal were originating from the 
TEM grids (Fig.28C). 
For comparison with TEM, the phase images of AFM were taken and analyzed 
(Fig.29). AFM phase imaging (Fig.29B) refers to record the phase shift signal of tip 
oscillation during tapping measurement. The phase shift presents the delay in 
oscillation of the cantilever because of different material (adhesion and stiffness). The 
images indicate that PLGA NPs contain smaller objects. Together with the TEM 
images and the data of the elemental analysis that the observed black spots loaded 
in PLGA NPs are magnetite (Fig.29A), these findings (TEM image and phase image 
of AFM), could be summed that NPs were formed by two kinds of different 
substances [188,189]. Based on the data of TEM and elemental analysis of iron 
core 
TEM grids 
Elemental analysis 
A 
B 
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signal (Fig.28 A,B,C) also the AFM phase imaging (Fig.29B) it was concluded that 
magnetite was successfully loaded into the PLGA particles. 
 
 
 
 
Figure 29. Determination of magnetite core on PLGA NP by TEM and AFM 
 
 
Figure 30. TEM image of magnetite NPs  
 
5.3.4 Imaging model hair shaft by using CLSM  
Imaging of entire/intact hair shafts has been not done yet. The limitation is 
regarding to the size and orientation of the hair shaft. Before going to the complex 
system such hair shaft in an excised human skin, we tried to create a simple and 
appropriate model of a hair shaft in terms of the length and orientation. The model 
was created based on agarose (subtitle 5.2.7). In this work we also performed 
confocal imaging as control. This measurement was conducted on several model hair 
shafts which were filled by fluorescently labeled PLGA NPs applied as cubic sliced 
agarose gel blocks. For these experiments different orientations of the model hair 
shafts were used as illustrated in Fig.31. It is important in order to obtain the good 
images of the model hair shaft because of limitations regarding the focal distance of 
the objective. 
 
TEM Image AFM Phase Imaging 
A B 
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 Figure 31.  Longitudinal and lateral orientation of model hair shaft containing  
 fluorescein PLGA in agarose cubic for CLSM measurement. 
 
In Fig.32 is shown the longitudinal position of model hair shaft. It is also clearly 
evidenced that visualizing the model from the top to bottom was not possible. This is 
because of the limitation of penetration depth of light and the restricted working 
distance of the microscope.  
 
 
 
 
 
 
 
 
 
 
   
 
Inside of the model hair shaft, the NPs could not be seen clearly because the void 
was covered by one layer of agarose when the top of model was faced objective 
lens. The diameter of void is ~0.5 mm (Fig.32) in the range of diameter of human hair 
follicles 0.1 - 0.5 mm [190,191] . Only for the lateral orientation the model hair shaft 
could be imaged in parts. The composed images are shown in Fig.33. The 
distribution of NPs in the model was not homogeneous. Some of NPs were 
agglomerated as seen as large and bright fluorescent spots. However, it could not be 
fully compared to the hair shaft in terms of the orientation and length not being fully 
representative to the real situation. Furthermore, the imaging using several single 
CLSM images to compose the structure of interest is time consuming.  
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     Agarose gel 
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Figure 32. CLSM images of longitudinally aligned model hair shaft containing  
fluoresceinamine-PLGA NP 
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                        Figure 33. CLSM images lateral position of model hair shaft containing  
                        fluoresceinamine-PLGA NP 
 
5.3.5 Imaging model hair shafts by using photoacoustic microscopy 
To answer the difficulties of imaging model hair shaft we introduced a 
promising method to image model hair shafts: photoacoustic microscopy. The 
measurement followed the procedure described before (section 5.2.8).  
Because of the high absorption of magnetite allowing to produce ultrasound 
when the laser light was applied, the samples should allow for successful imaging. 
The produced ultrasound was transferred as an image by using ultrasound 
transducer and the model hair shaft could be visualized. 
Therefore, pure magnetite particles (Fig.34C) and PLGA NPs loading 
magnetite (Fig.34B) were filled in the model as control blank PLGA NP were used 
(Fig.34A). The photoacoustic images are shown in Fig.34. The measurement was 
quite fast and relatively easy because taking the image of the different model hair 
shafts from the top could be conducted simultaneously. Imaging reconstruction also 
allows displaying the side view of model hair shaft as showed in Fig.35.  
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Figure 34. Top view of photoacoustic image of three model hair shafts containing particles. A) pure 
PLGA particles for control B) magnetite-PLGA NP and C) pure magnetite particles 
 
The tilted orientation is a common position with an angle around 45 to 60° for 
hair shafts [192,193]. The size and the orientation did not cause any problems in 
imaging. Based on Fig.35, the length of the model hair shaft is around 1.1 mm.  
Due to the length distribution of human hair follicles in the range of 0.5-3 mm 
[194], we assumed that 1.1 mm is a valid size for our model being at least in the right 
range. Additionally, it was seen, that the covering layer made of agarose does not 
limit the imaging process in terms of the depth and the size of model hair shaft.  
 
Oberfläche
Probe C
 
Figure 35. Photoacoustic images representing a side view of a model hair shaft containing  magnetite-
PLGA NP (red ellipse), the dashed line indicates the location of the covering layer.  
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5. 4. Conclusions 
In the present investigation, the formulation of PLGA NPs loading magnetite 
was obtained. The NPs were prepared by nanoprecipitation and single emulsion 
methods. By using single emulsion method in contrast to nanoprecipitation, spherical 
particles could be produced with a narrow distribution. By applying higher 
concentrations of magnetite (≥2 mg/mL) the NPs have shown broad unwanted 
distribution of particles. The successful incorporation of magnetite into the polymer 
NPs could be determined by using AFM and TEM images in combination elemental 
analysis. PLGA NPs loading magnetite were then applied to visualize model hair 
shafts embedded in agarose gel representing the hair follicle dimensions. The model 
hair shafts containing PLGA NP loading magnetite could be easily imaged by 
photoacoustic microscopy. Hence photoacoustic microscopy is an appropriate and 
promising technique to visualize intact hair follicles as large objects. This technique 
could be used to overcome the limitations of classical CLSM technique regarding the 
large scale and orientation of hair follicles for determining the localization of drug 
carrier systems. 
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VI. SUMMARY 
 
  
Hair loss is a case which can be found in men and women. Usually, if hair loss 
occurs in an every day manner, it will grow again by regeneration of new hair. When the 
amount of hair loss is more than the amount of hair growth, it will decrease the total 
amount of hairs. This condition could happen everyday and cause baldness. Feared by 
everyone, baldness is caused by continuous hair loss. Disruption of hair growth is 
influenced by internal and external factors of human body. Baldness is a rare case. 
Although rare, this is a worrying case for the patients. Nowadays, it has been attempted 
the way to prevent and treat hair loss by commercial products such as lotions, creams 
and shampoos. These commercial products containing caffeine in non particulate 
formulations are available on the market. Based on the recent research, it was known 
that the particulate formulation has better penetration into the hair follicles. A particulate 
formulation still needs to be developed, especially a nanoparticulate formulation which is 
promising product for hair follicles application. The investigations of this kind of 
formulation have been indicating the significant progress. Some of these investigations 
are aimed to develop pharmaceutical dosage forms because only a limited number of 
them employed nanoparticles (NPs). In the pharmaceutical field, NPs are produced with 
a uniform size. This NPs loading drug are intended to deliver and target the drug to the 
human body. Because NPs can reach the specific target, this should be able to diminish 
the side effect of drug.    
 Based on these informations, this study aimed to develop and characterize a 
particulate formulation by utilizing a biocompatible and biodegradable polymer such as 
chitosan and poly(lactic-co-glicolic acid) (PLGA) to form NPs loading caffeine. 
Interaction between chitosan and caffeine was determined by Fourier Transform Infrared 
Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC) and by a solubilization 
study of caffeine. FTIR and DSC measurements indicated that the interaction between 
chitosan and caffeine is based on the formation of a complex. The solubilization study 
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showed the ability of chitosan to solve insoluble caffeine in a saturated dispersion and 
increase the saturation concentration. NPs loading caffeine were prepared by combining 
chitosan and PLGA to form chitosan-PLGA NPs (by single emulsion method) and solely 
PLGA NPs (by double emulsion method). Data of NPs characterization showed that NPs 
have a spherical shape. Especially, NPs made from chitosan-PLGA showed better 
properties than that of PLGA NPs in terms of particle size and size distribution. Loading 
of caffeine was increased by using chitosan. Caffeine release from NPs is slower than 
passive diffusion of solved caffeine which is not formulated in the form of particles.  
 The difficulty of delivering drug across the skin is prevalent. One of the strategies 
gaining more attention over the last years is the targeting of the hair follicles. Upon 
application the carrier system accumulates in the hair follicles and can release its load. 
The common/standard visualization technique is confocal laser scanning microscopy, 
but it has several problems originating from the physical size of the hair follicles and their 
orientation in skin. An intriguing alternative to fluorescence-based techniques is 
photoacoustic microscopy. Optoacoustic imaging is a novel method that based on the 
specific absorption of light in the near infrared region. The absorber such as iron oxide is 
irradiated by short laser pulses in the sub-nanosecond range generating broadband 
acoustic signals as a result of the thermoelastic effect. These signals propagating 
through the samples can be obtained with adequate ultrasound transducers. When 
compared with conventional ultrasound imaging, optoacoustic techniques have the 
advantage of higher contrast. Optoacoustic signal amplitudes are proportional to the 
local absorption coefficient µa. Since the absorptions coefficient is dependent on the 
concentration of absorbing material, this effect can be utilized in order to assess the 
suitability of different material types (magnetite or magnetite-loaded polymer) as contrast 
agents. 
 As a possible label a magnetite core was introduced to the polymeric PLGA 
particles synthesized for drug delivery purposes. This combination of materials allows 
achieving magnetic properties as well as biocompatibility and biodegradability of the 
carrier. Furthermore, a good model system mimicking hair follicles would facilitate ex 
vivo investigations. Hence, preparation and characterization of magnetite PLGA NPs 
was in focus and the evaluation of a model hair shaft which could be imaged by 
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photoacoustic microscopy. The model hair shaft was prepared by using a syringe which 
was immersed into a 1.75% agarose gel (in a Petri dish). After solidification and 
retraction of the syringe, a void had been formed (serving as the model). This void was 
then filled with a suspension of NPs. The results showed that magnetite-PLGA NPs 
were successfully produced by utilizing 1 mg/mL magnetite and the model hair shaft 
containing magnetite-PLGA could consequently be imaged by using photoacoustic 
microscopy while confocal microscopy imaging was time consuming and complicated 
which could not image the large structure.   
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ABBREVIATIONS 
 
 
AFM  = Atomic force microscopy 
API  = Active pharmaceutical ingredient 
AuNPs = Gold nanoparticles 
cAMP  = Cyclic adenosine monophosphate 
Chit  = Chitosan 
CLSM  = Confocal laser scanning microscopy 
Da  = Dalton 
DHT  = Dihydrotestosterone 
DLS  = Dynamic light scattering 
DMF  = Dimethyl formamide 
DMSO = Dimethyl Sulfoxide 
DSC  = Differential scanning calorimetry 
EE  = Encapsulation efficiency  
FDA  = Food and drug administration 
FDC  = Franz diffusion cell 
FTIR  = Fourier transform infrared  
FWHM = Full width half maximum 
HF  = Hair follicles 
HPLC  = High performance liquid chromatography 
MNPs  = Magnetite nanoparticles 
MRI  = Magnetic resonance imaging 
MT  = Magnetite 
MWCO= Molecular weight cut off 
NPs  = Nanoparticles  
PAM  = Photoacoustic Microscopy 
PBS  = Phosphate buffered saline 
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PDI  = Polydispersity index 
PLGA  = Poly(lactic-co-glycolic acid) 
PVA  = Polyvinyl alcohol 
SLNs  = Solid lipid nanoparticles 
SC  = Stratum corneum 
SEM  = Scanning electron microscopy 
5α−Red = 5α−Reductase  
TEM  = Transmission electron microscopy 
TPP  = Tripolyphosphate  
UV  = Ultraviolet 
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